<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523418302939</prism:url><dc:identifier>doi:10.1016/j.ejmech.2018.03.053</dc:identifier><eid>1-s2.0-S0223523418302939</eid><prism:doi>10.1016/j.ejmech.2018.03.053</prism:doi><pii>S0223-5234(18)30293-9</pii><dc:title>Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>151</prism:volume><prism:startingPage>752</prism:startingpage><prism:endingPage>764</prism:endingpage><prism:pageRange>752-764</prism:pagerange><dc:format>text/xml</dc:format><prism:coverDate>2018-05-10</prism:coverdate><prism:coverDisplayDate>10 May 2018</prism:coverdisplaydate><prism:copyright>© 2018 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Guo, Jianpeng</dc:creator><dc:creator>Yu, Wenying</dc:creator><dc:creator>Cai, Guiping</dc:creator><dc:creator>Zhang, Wenda</dc:creator><dc:creator>Li, Shanshan</dc:creator><dc:creator>Zhu, Jiawen</dc:creator><dc:creator>Song, Dongmei</dc:creator><dc:creator>Kong, Lingyi</dc:creator><dc:description>
                  Persistent activated STAT3 has a striking correlation with cancer development and inhibition of STAT3 signaling pathway is a novel therapeutic way for human cancers. Among STAT family, STAT1 and STAT3 play opposite roles in tumorigenesis. However, the discovery of selective STAT3 inhibitors is still challenging to date. In this study, a series of small-molecular (MW < 500) benzensulfanilamide derivatives were designed to selectively suppress STAT3 activation for anti-cancer treatment. The most potent compound 11 inhibited both overexpressed and IL-6 induced STAT3 phosphorylation, whereas 11 displayed little effect on the phosphorylation of other STAT isoforms STAT1, STAT5, demonstrating 11 was a selective STAT3 inhibitor. Meanwhile, 11 dismissed STAT3 DNA binding activity and colony formation. In addition, 11 elevated the ROS level and induced apoptosis of cancer cells. Furthermore, 11 effectively suppressed tumor growth in an in vivo mouse-xenograft model.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>Antitumor activity</dcterms:subject><dcterms:subject>Sulfonamide</dcterms:subject><dcterms:subject>Selectivity</dcterms:subject><dcterms:subject>Structure-based drug design</dcterms:subject><dcterms:subject>STAT3 phosphorylation</dcterms:subject><dcterms:subject>Apoptosis</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523418302939" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523418302939" rel="scidir"/></link></coredata><objects><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="94" size="14087">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="63" size="7991">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="199" height="164" size="15597">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="176" height="164" size="20650">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr10.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="218" height="164" size="31510">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="58" size="14960">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="71" size="19913">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="148" size="20763">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="200" height="163" size="23938">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="181" height="164" size="17630">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="102" size="14186">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="gr9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="63" size="15252">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr9.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="86" height="164" size="11668">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="466" height="200" size="39653">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="495" height="142" size="25312">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="557" height="459" size="70276">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="557" height="518" size="91160">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr10.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="557" height="419" size="96382">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="669" height="177" size="68243">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="557" height="181" size="63729">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="557" height="376" size="66564">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="268" height="219" size="38224">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="557" height="504" size="82709">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="557" height="259" size="56870">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="713" height="204" size="59895">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr9.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="387" height="736" size="80489">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2066" height="886" size="203735">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2193" height="627" size="100606">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2469" height="2034" size="407645">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2469" height="2294" size="678511">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2467" height="1855" size="645802">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2961" height="783" size="444080">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2469" height="804" size="392597">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2469" height="1667" size="516492">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1189" height="972" size="197948">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2469" height="2236" size="578506">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2469" height="1148" size="336200">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3158" height="905" size="381629">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-gr9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1713" height="3260" size="503762">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-sc1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc2" category="standard" type="APPLICATION" multimediatype="ZIP file" mimetype="application/zip" size="22535">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-mmc2.zip?httpAccept=%2A%2F%2A</object><object ref="mmc3" category="standard" type="APPLICATION" multimediatype="ZIP file" mimetype="application/zip" size="22533">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-mmc3.zip?httpAccept=%2A%2F%2A</object><object ref="mmc4" category="standard" type="APPLICATION" multimediatype="ZIP file" mimetype="application/zip" size="22526">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-mmc4.zip?httpAccept=%2A%2F%2A</object><object ref="mmc5" category="standard" type="APPLICATION" multimediatype="ZIP file" mimetype="application/zip" size="22625">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-mmc5.zip?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Microsoft Word file" mimetype="application/word" size="36729059">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523418302939-mmc1.docx?httpAccept=%2A%2F%2A</object></objects><scopus-id>85045437870</scopus-id><scopus-eid>2-s2.0-85045437870</scopus-eid><pubmed-id>29674294</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85045437870" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20180404">2018-04-04</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20180404">2018-04-04</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20180424">2018-04-24</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20180424">2018-04-24</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2019-01-28T08:46:48</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523418302939</xocs:eid>
      <xocs:pii-formatted>S0223-5234(18)30293-9</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523418302939</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2018.03.053</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.2</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523418X00087</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20190128">2019-01-28T09:08:10.964029Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20180510</xocs:date-search-begin>
      <xocs:year-nav>2018</xocs:year-nav>
      <xocs:indexeddate epoch="1522851496">2018-04-04T14:18:16.421885Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast footnotes grantnumber grantsponsor grantsponsorid highlightsabst orcid otherkwds primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>151</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>151</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 151</xocs:vol-iss-suppl-text>
      <xocs:sort-order>53</xocs:sort-order>
      <xocs:first-fp>752</xocs:first-fp>
      <xocs:last-lp>764</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>752</xocs:first-page>
         <xocs:last-page>764</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20180510</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>10 May 2018</xocs:cover-date-text>
      <xocs:cover-date-start>2018-05-10</xocs:cover-date-start>
      <xocs:cover-date-year>2018</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Research paper</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2018 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>DISCOVERYNEWBENZENSULFONAMIDEDERIVATIVESTRIPEDALSTAT3INHIBITORS</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>GUO</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>J</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Design and chemistry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>MTT assay and SAR analysis</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Molecular docking study</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compound <ce:bold>11</ce:bold> inhibited STAT3 tyrosine phosphorylation</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compound <ce:bold>11</ce:bold> inhibited interleukin-6 (IL-6) induced STAT3 phosphorylation</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compound <ce:bold>11</ce:bold> inhibited STAT3 DNA-binding activity</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.7</xocs:item-toc-label>
               <xocs:item-toc-section-title>Selectivity of compound <ce:bold>11</ce:bold> among STAT isoforms</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.8</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compound <ce:bold>11</ce:bold> affected the expression of STAT3 related proteins</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.9</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compound <ce:bold>11</ce:bold> induced apoptosis in cancer cells</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.10</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compound <ce:bold>11</ce:bold> induced the ROS generation in cancer cells</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.11</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compound <ce:bold>11</ce:bold> reduced colony formation <ce:italic>in vitro</ce:italic>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.12</xocs:item-toc-label>
               <xocs:item-toc-section-title>In vivo study of compound <ce:bold>11</ce:bold>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusions</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Materials and methods</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the synthesis of <ce:bold>1</ce:bold> and <ce:bold>17</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>1</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-(((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>17</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the synthesis of <ce:bold>2</ce:bold>–<ce:bold>16</ce:bold> and <ce:bold>18</ce:bold>–<ce:bold>25</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((4-isopropylbenzyl) (4-methylbenzyl)amino)benzenesulfonamide(<ce:bold>2</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((4-isopropylbenzyl) (2-(trifluoromethyl)benzyl)amino)benzenesulfonamide (<ce:bold>3</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((4-isopropylbenzyl) (3-(trifluoromethyl)benzyl)amino)benzenesulfonamide (<ce:bold>4</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((4-isopropylbenzyl) (4-(trifluoromethyl)benzyl)amino)benzenesulfonamide (<ce:bold>5</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.5</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((2-fluorobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>6</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.6</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((3-fluorobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>7</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.7</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((4-fluorobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>8</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.8</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((2,3-difluorobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>9</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.9</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((3,4-difluorobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>10</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.10</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((4-isopropylbenzyl) ((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>11</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.11</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((2-chlorobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>12</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.12</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((3-chlorobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>13</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.13</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((4-chlorobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>14</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.14</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((3-bromobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>15</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.15</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((4-isopropylbenzyl) (naphthalen-1-ylmethyl)amino)benzenesulfonamide (<ce:bold>16</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.16</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((3,5-dimethoxybenzyl) ((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>18</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.17</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((3-methoxybenzyl) ((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>19</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.18</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((4-ethoxybenzyl) ((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>20</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.19</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((3-methylbenzyl) ((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>21</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.20</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((4-methylbenzyl) ((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>22</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.21</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((4-ethylbenzyl) ((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>23</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.22</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((4-fluorobenzyl) ((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>24</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.23</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((4-chlorobenzyl) ((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>25</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the synthesis of <ce:bold>26</ce:bold>–<ce:bold>29</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((4-isopropylbenzyl) (3-(trifluoromethyl)benzyl)amino)-N-(3-(trifluoromethyl)benzyl)benzenesulfonamide (<ce:bold>26</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>N-(3-chlorobenzyl)-3-((3-chlorobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>27</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>N-(3-bromobenzyl)-3-((3-bromobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>28</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>N-(4-chlorobenzyl)-3-((4-chlorobenzyl) ((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>29</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Molecular docking studies</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Cell line and cell culture</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Cell viability assays</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>Western blot assays</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>IL-6 induction of STAT3 phosphorylation</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.7</xocs:item-toc-label>
               <xocs:item-toc-section-title>Nuclear extract preparation and gel shift assays</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.8</xocs:item-toc-label>
               <xocs:item-toc-section-title>Annexin V-APC/7-AAD double staining to detect apoptosis</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.9</xocs:item-toc-label>
               <xocs:item-toc-section-title>ROS evaluation by flow cytometry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.10</xocs:item-toc-label>
               <xocs:item-toc-section-title>Colony survival assays</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.11</xocs:item-toc-label>
               <xocs:item-toc-section-title>In vivo tumor studies</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.12</xocs:item-toc-label>
               <xocs:item-toc-section-title>Acute toxicity tests</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>MIKLOSSY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>611</xocs:ref-first-fp>
            <xocs:ref-last-lp>629</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>DEBNATH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>6645</xocs:ref-first-fp>
            <xocs:ref-last-lp>6668</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1181</xocs:ref-first-fp>
            <xocs:ref-last-lp>1191</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>AGGARWAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>151</xocs:ref-first-fp>
            <xocs:ref-last-lp>169</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>FLETCHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>825</xocs:ref-first-fp>
            <xocs:ref-last-lp>833</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>FLETCHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1459</xocs:ref-first-fp>
            <xocs:ref-last-lp>1470</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>PAGE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>7190</xocs:ref-first-fp>
            <xocs:ref-last-lp>7200</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>97</xocs:ref-first-fp>
            <xocs:ref-last-lp>105</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>BOWMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>2474</xocs:ref-first-fp>
            <xocs:ref-last-lp>2488</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>BROMBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>2468</xocs:ref-first-fp>
            <xocs:ref-last-lp>2473</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>BENEKLI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>4422</xocs:ref-first-fp>
            <xocs:ref-last-lp>4432</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>AVALLE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>65</xocs:ref-first-fp>
            <xocs:ref-last-lp>72</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>KRASKOUSKAYA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>3337</xocs:ref-first-fp>
            <xocs:ref-last-lp>3370</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>CHOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1993</xocs:ref-pub-year>
            <xocs:ref-first-fp>767</xocs:ref-first-fp>
            <xocs:ref-last-lp>778</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>BECKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>145</xocs:ref-first-fp>
            <xocs:ref-last-lp>151</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>PARK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>254</xocs:ref-first-fp>
            <xocs:ref-last-lp>265</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>736</xocs:ref-first-fp>
            <xocs:ref-last-lp>746</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>FURTEK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>308</xocs:ref-first-fp>
            <xocs:ref-last-lp>318</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>SONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>4700</xocs:ref-first-fp>
            <xocs:ref-last-lp>4705</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>4402</xocs:ref-first-fp>
            <xocs:ref-last-lp>4412</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>2718</xocs:ref-first-fp>
            <xocs:ref-last-lp>2731</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>LIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>39</xocs:ref-first-fp>
            <xocs:ref-last-lp>50</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>SIDDIQUEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>7391</xocs:ref-first-fp>
            <xocs:ref-last-lp>7396</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1398</xocs:ref-first-fp>
            <xocs:ref-last-lp>1409</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>9623</xocs:ref-first-fp>
            <xocs:ref-last-lp>9628</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1381</xocs:ref-first-fp>
            <xocs:ref-last-lp>1387</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>TURKSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>261</xocs:ref-first-fp>
            <xocs:ref-last-lp>269</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>SIDDIQUEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>787</xocs:ref-first-fp>
            <xocs:ref-last-lp>798</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>538</xocs:ref-first-fp>
            <xocs:ref-last-lp>550</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1006</xocs:ref-first-fp>
            <xocs:ref-last-lp>1018</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>46352</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>5592</xocs:ref-first-fp>
            <xocs:ref-last-lp>5596</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>KAPTEIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1996</xocs:ref-pub-year>
            <xocs:ref-first-fp>5961</xocs:ref-first-fp>
            <xocs:ref-last-lp>5964</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>BOATRIGHT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>725</xocs:ref-first-fp>
            <xocs:ref-last-lp>731</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>SIMON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>415</xocs:ref-first-fp>
            <xocs:ref-last-lp>418</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>GUOX2018X752</xocs:refkey3>
         <xocs:refkey4lp>GUOX2018X752X764</xocs:refkey4lp>
         <xocs:refkey4ai>GUOX2018X752XJ</xocs:refkey4ai>
         <xocs:refkey5>GUOX2018X752X764XJ</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2020-04-24T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2020-04-24T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-embargo-status>UnderEmbargo</xocs:sa-embargo-status>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2018 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(18)30293-9</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523418302939</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523418302939</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2018.03.053</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2019-01-28T09:08:10.964029Z</xocs:timestamp>
         <xocs:cover-date-start>2018-05-10</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/MAIN/application/pdf/ac24dc715549c237f5fca740f22de833/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>2730256</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>13</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523418302939-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/PREVIEW/image/png/494a16c6faa4fe92a9d32bd56daf4f6d/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>56839</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/fx1/THUMBNAIL/image/gif/bda868a75da1293ef043f77255179032/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>14087</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/fx2/THUMBNAIL/image/gif/f02a80d1b63542f9aa61ddebf6a107d1/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7991</xocs:filesize>
               <xocs:pixel-height>63</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr1/THUMBNAIL/image/gif/d82f3c6c59a51876496178ec3abdedce/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>15597</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>199</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr10/THUMBNAIL/image/gif/103a1f8ff8bb7b418ccfd8e5b2082f52/gr10.sml</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>20650</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>176</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr2/THUMBNAIL/image/gif/d43ae830439925447ff13554be3f9f37/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>31510</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>218</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr3/THUMBNAIL/image/gif/9c7f60f47eafd035ac0b818db58a933f/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>14960</xocs:filesize>
               <xocs:pixel-height>58</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr4/THUMBNAIL/image/gif/3eefc19bec847af67bed07f14899ef75/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>19913</xocs:filesize>
               <xocs:pixel-height>71</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr5/THUMBNAIL/image/gif/77834997afaea3586f887b11ace248c1/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>20763</xocs:filesize>
               <xocs:pixel-height>148</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr6/THUMBNAIL/image/gif/8a41e7a68fcb226a6e314ad58f78e8f9/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>23938</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>200</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr7/THUMBNAIL/image/gif/efdba42ef431b5b35fcc924a4bc56def/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>17630</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>181</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr8/THUMBNAIL/image/gif/cdbd4c227adfd63e3128dc5bab26a078/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>14186</xocs:filesize>
               <xocs:pixel-height>102</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr9/THUMBNAIL/image/gif/e0c1d9edac3262e32628efee7e6b9f57/gr9.sml</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>15252</xocs:filesize>
               <xocs:pixel-height>63</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/sc1/THUMBNAIL/image/gif/a85e8315e41b377823ee3eeaf795d9eb/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11668</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>86</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/fx1/DOWNSAMPLED/image/jpeg/e1fe5922b42b84a1e7800c3956955c13/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>39653</xocs:filesize>
               <xocs:pixel-height>200</xocs:pixel-height>
               <xocs:pixel-width>466</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/fx2/DOWNSAMPLED/image/jpeg/62f35370e697bf0f3eec511ca4769be2/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>25312</xocs:filesize>
               <xocs:pixel-height>142</xocs:pixel-height>
               <xocs:pixel-width>495</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr1/DOWNSAMPLED/image/jpeg/e8f5f33ed2537c1e6722d88c2abb9fb2/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>70276</xocs:filesize>
               <xocs:pixel-height>459</xocs:pixel-height>
               <xocs:pixel-width>557</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr10/DOWNSAMPLED/image/jpeg/3ba37068f27b3f03c43099cdd3bc9437/gr10.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>91160</xocs:filesize>
               <xocs:pixel-height>518</xocs:pixel-height>
               <xocs:pixel-width>557</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr2/DOWNSAMPLED/image/jpeg/93d6278bab7c072b4c6db2c96d5b1e68/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>96382</xocs:filesize>
               <xocs:pixel-height>419</xocs:pixel-height>
               <xocs:pixel-width>557</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr3/DOWNSAMPLED/image/jpeg/47a3639acd7d597d4567d11500b8bbbb/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>68243</xocs:filesize>
               <xocs:pixel-height>177</xocs:pixel-height>
               <xocs:pixel-width>669</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr4/DOWNSAMPLED/image/jpeg/6e3ddf7319fea0e522f15c340325b179/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>63729</xocs:filesize>
               <xocs:pixel-height>181</xocs:pixel-height>
               <xocs:pixel-width>557</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr5/DOWNSAMPLED/image/jpeg/ff7ccd793021f0fef249535bae7d178e/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>66564</xocs:filesize>
               <xocs:pixel-height>376</xocs:pixel-height>
               <xocs:pixel-width>557</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr6/DOWNSAMPLED/image/jpeg/5bfb3d3aa46c1673ac92b6efd78097e4/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>38224</xocs:filesize>
               <xocs:pixel-height>219</xocs:pixel-height>
               <xocs:pixel-width>268</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr7/DOWNSAMPLED/image/jpeg/2f6f4a522796def0ca0761b6ba06bddf/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>82709</xocs:filesize>
               <xocs:pixel-height>504</xocs:pixel-height>
               <xocs:pixel-width>557</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr8/DOWNSAMPLED/image/jpeg/dc76ad62a070905169c81fccb9ac7802/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>56870</xocs:filesize>
               <xocs:pixel-height>259</xocs:pixel-height>
               <xocs:pixel-width>557</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr9/DOWNSAMPLED/image/jpeg/bb8fc6fcece1c13a8b701d411a06ef8c/gr9.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>59895</xocs:filesize>
               <xocs:pixel-height>204</xocs:pixel-height>
               <xocs:pixel-width>713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/sc1/DOWNSAMPLED/image/jpeg/749e8fe63242a34267ceb060a8c4578d/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>80489</xocs:filesize>
               <xocs:pixel-height>736</xocs:pixel-height>
               <xocs:pixel-width>387</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/fx1/HIGHRES/image/jpeg/83d72438785669ac6c19d95c4f7566ec/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>203735</xocs:filesize>
               <xocs:pixel-height>886</xocs:pixel-height>
               <xocs:pixel-width>2066</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/fx2/HIGHRES/image/jpeg/6395bb42050748b2289b603d8d73ff30/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>100606</xocs:filesize>
               <xocs:pixel-height>627</xocs:pixel-height>
               <xocs:pixel-width>2193</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr1/HIGHRES/image/jpeg/b1324ca6d44eedb10883b3ee0666f779/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>407645</xocs:filesize>
               <xocs:pixel-height>2034</xocs:pixel-height>
               <xocs:pixel-width>2469</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr10/HIGHRES/image/jpeg/7080d3daafccb8b79a16f3759b3fe3ee/gr10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>678511</xocs:filesize>
               <xocs:pixel-height>2294</xocs:pixel-height>
               <xocs:pixel-width>2469</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr2/HIGHRES/image/jpeg/4f4218c05b08d97bc10788f4c1cfafda/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>645802</xocs:filesize>
               <xocs:pixel-height>1855</xocs:pixel-height>
               <xocs:pixel-width>2467</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr3/HIGHRES/image/jpeg/33c658ff1b114c5cbccffb1b635fba0c/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>444080</xocs:filesize>
               <xocs:pixel-height>783</xocs:pixel-height>
               <xocs:pixel-width>2961</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr4/HIGHRES/image/jpeg/5bbe6230dbc56137fe15ed2ba4f0341f/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>392597</xocs:filesize>
               <xocs:pixel-height>804</xocs:pixel-height>
               <xocs:pixel-width>2469</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr5/HIGHRES/image/jpeg/abd64ef95ad5fcdb226d571fdd8425dc/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>516492</xocs:filesize>
               <xocs:pixel-height>1667</xocs:pixel-height>
               <xocs:pixel-width>2469</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr6/HIGHRES/image/jpeg/57219ef993a2383f76593aff61758528/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>197948</xocs:filesize>
               <xocs:pixel-height>972</xocs:pixel-height>
               <xocs:pixel-width>1189</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr7/HIGHRES/image/jpeg/a40fad50ac70b453773e6b207a78fb06/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>578506</xocs:filesize>
               <xocs:pixel-height>2236</xocs:pixel-height>
               <xocs:pixel-width>2469</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr8/HIGHRES/image/jpeg/15d7b018fe4c79f91d7e7d484ec63281/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>336200</xocs:filesize>
               <xocs:pixel-height>1148</xocs:pixel-height>
               <xocs:pixel-width>2469</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-gr9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/gr9/HIGHRES/image/jpeg/62c06116cc8e2af17c9233a4673013d3/gr9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>381629</xocs:filesize>
               <xocs:pixel-height>905</xocs:pixel-height>
               <xocs:pixel-width>3158</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-sc1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/sc1/HIGHRES/image/jpeg/f5c16e9ba156e4b9abe0f6ee842f3346/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>503762</xocs:filesize>
               <xocs:pixel-height>3260</xocs:pixel-height>
               <xocs:pixel-width>1713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-mmc2.zip</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/mmc2/MAIN/application/zip/9a35c4506ff5b79b69887df1112c15c9/mmc2.zip</xocs:ucs-locator>
               <xocs:file-basename>mmc2</xocs:file-basename>
               <xocs:filename>mmc2.zip</xocs:filename>
               <xocs:extension>zip</xocs:extension>
               <xocs:filesize>22535</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-mmc3.zip</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/mmc3/MAIN/application/zip/c732bc557ed348db5ad441226153c128/mmc3.zip</xocs:ucs-locator>
               <xocs:file-basename>mmc3</xocs:file-basename>
               <xocs:filename>mmc3.zip</xocs:filename>
               <xocs:extension>zip</xocs:extension>
               <xocs:filesize>22533</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-mmc4.zip</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/mmc4/MAIN/application/zip/86997681e026697b81a669cd1884de3a/mmc4.zip</xocs:ucs-locator>
               <xocs:file-basename>mmc4</xocs:file-basename>
               <xocs:filename>mmc4.zip</xocs:filename>
               <xocs:extension>zip</xocs:extension>
               <xocs:filesize>22526</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-mmc5.zip</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/mmc5/MAIN/application/zip/ae7312184b412cac948afbfa4c37801d/mmc5.zip</xocs:ucs-locator>
               <xocs:file-basename>mmc5</xocs:file-basename>
               <xocs:filename>mmc5.zip</xocs:filename>
               <xocs:extension>zip</xocs:extension>
               <xocs:filesize>22625</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523418302939-mmc1.docx</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523418302939/mmc1/MAIN/application/vnd.openxmlformats-officedocument.wordprocessingml.document/ea42fc1a9af39b43b5719dc1ea719a29/mmc1.docx</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.docx</xocs:filename>
               <xocs:extension>docx</xocs:extension>
               <xocs:filesize>36729059</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.5" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>10318</aid>
            <ce:pii>S0223-5234(18)30293-9</ce:pii>
            <ce:doi>10.1016/j.ejmech.2018.03.053</ce:doi>
            <ce:copyright type="full-transfer" year="2018">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Representative small-molecule STAT3 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0040">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418302939/gr1"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">
                     <ce:bold>Design strategy.</ce:bold> The skeleton of <ce:bold>36</ce:bold> was colored purple. <ce:bold>11</ce:bold> was shown in stick-ball and its skeleton was colored turquoise blue. The surface of SH2 domain was colored according to element property. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0045">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418302939/gr2"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">
                     <ce:bold>Docking model of compounds with sulfanilamide fragment at <ce:italic>ortho-</ce:italic>, <ce:italic>meta-</ce:italic> and <ce:italic>para-</ce:italic>position binding to the STAT3 SH2 domain (PDB: 1BG1) generated by AutoDock4.2.</ce:bold> STAT3 protein was represented as white ribbon. The key residues were shown. Hydrogen bonds were represented by green dashes. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0050">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418302939/gr3"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">
                     <ce:bold>Docking model of 11 binding to the STAT3 SH2 domain (PDB: 1BG1) generated by AutoDock4.2.</ce:bold> (A) <ce:bold>11</ce:bold> was colored by atom type. The surface of SH2 domain was colored according to element property. (B) STAT3 protein was represented as white ribbon. The key residues were shown. Hydrogen bonds were represented by green dashes. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0055">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418302939/gr4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">
                     <ce:bold>Compound 11 inhibited STAT3 activation and didn't inhibit STAT1 and STAT5 phosphorylation.</ce:bold> (A) The effect of compound <ce:bold>11</ce:bold> on p-STAT3 (Y705), STAT3, p-STAT1 (Y701), STAT1, p-STAT5 (Y694) and STAT5 protein expression by western blot analysis using GAPDH as a control. (B) Compound <ce:bold>11</ce:bold> and <ce:bold>36</ce:bold> inhibited STAT3 and STAT1 phosphorylation in HCT-116 cells at 10 μM for 20 h by western blot analysis. (C) Compound <ce:bold>11</ce:bold> inhibited STAT3 phosphorylation induced by IL-6 in HCT-116 cells by western blot analysis. (D) EMSA analysis of nuclear extracts of equal total protein containing activated STAT3 from HCT-116 cells treated with compound <ce:bold>11</ce:bold> for 20 h after incubation with hSIE probe that binds STAT3.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0060">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418302939/gr5"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">
                     <ce:bold>Compound 11 affected the expressions of STAT3-regulated proteins.</ce:bold> Western blot analysis of <ce:italic>p</ce:italic>-Src, Src, <ce:italic>p</ce:italic>-Erk, Erk, Bcl-2 and Cyclin D1 levels in whole-cell lysates of equal total protein prepared from HCT-116 cells treated with compound <ce:bold>11</ce:bold> for 20 h.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0065">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418302939/gr6"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig. 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">
                     <ce:bold>Compound 11 induced tumor cells apoptosis <ce:italic>in vitro</ce:italic>.</ce:bold> (A) The Annexin V/7-AAD staining assay was used to analyze the compound <ce:bold>11</ce:bold> induced apoptosis in HCT-116 cells detected by flow cytometry. (B) Percent of HCT-116 cells undergoing apoptosis after treatment with <ce:bold>11</ce:bold> for 20 h. Data are the mean value ± SD obtained from three independent experiments. (C) Western blot analysis with antibodies specific for Caspase-3, Cleaved Caspase-3, Caspase-7, Cleaved Caspase-7, Caspase-9, Cleaved Caspase-9 and the house keeping protein GAPDH in HCT-116 cells incubated with compound <ce:bold>11</ce:bold> for 20 h ***p < 0.001, **p < 0.01.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0070">Fig. 7</ce:alt-text>
               <ce:link locator="gr7" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418302939/gr7"/></ce:link>
            </ce:figure>
            <ce:figure id="fig8">
               <ce:label>Fig. 8</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">
                     <ce:bold>Compound 11 induced ROS generation.</ce:bold> (A) <ce:bold>11</ce:bold> increased ROS generation measured by DCFH-DA staining and analyzed by flow cytometry. (B) Mean value fluorescence intensity of HCT-116 cells after treatment with <ce:bold>11</ce:bold> for 20 h ***p < 0.001, **p < 0.01.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0075">Fig. 8</ce:alt-text>
               <ce:link locator="gr8" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418302939/gr8"/></ce:link>
            </ce:figure>
            <ce:figure id="fig9">
               <ce:label>Fig. 9</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0050" view="all">
                     <ce:bold>Compound 11 inhibited cancer cells proliferation <ce:italic>in vitro</ce:italic>.</ce:bold> Colony forming assay was implemented to assess the anti-proliferative activity of the compound <ce:bold>11</ce:bold> with respect to HCT-116 cells.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0080">Fig. 9</ce:alt-text>
               <ce:link locator="gr9" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418302939/gr9"/></ce:link>
            </ce:figure>
            <ce:figure id="fig10">
               <ce:label>Fig. 10</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="fspara0055" view="all">
                     <ce:bold>Compound 11 inhibited the growth of human sarcoma xenograft tumors <ce:italic>in vivo</ce:italic>.</ce:bold> (A) Anatomical nude mice's tumor tissue untreated or treated with <ce:bold>11</ce:bold> (10 and 20 mg/kg). (B) Inhibition percentage of mice's tumor tissues upon treatment of <ce:bold>11</ce:bold> (10 and 20 mg/kg). (C) The growing curves of mice's tumor volume. (D) The growing curves of mice's body weight. (E) Western blot analysis of p-STAT3 (Y705) and STAT3 levels in tumor tissues prepared from control or mice treated with <ce:bold>11</ce:bold> (10 and 20 mg/kg). ***p < 0.001, **p < 0.01.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0085">Fig. 10</ce:alt-text>
               <ce:link locator="gr10" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418302939/gr10"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="fspara0060" view="all">Synthesis of series A-C compounds.Reagents and conditions: (a) (i) AcOH, 4 Å molecular sieves, DCM, 30 min; (ii) Na(OAc)3BH3, rt, overnight; (b) K2CO3, MeCN, reflux, 10 h; (c) K2CO3, MeCN, reflux, overnight.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0090">Scheme 1</ce:alt-text>
               <ce:link locator="sc1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418302939/sc1"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl1" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="tspara0010" view="all">Antiproliferative activity of the designed compounds and the control compound <ce:bold>36</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0095">Table 1</ce:alt-text>
               <ce:link locator="fx2" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418302939/fx2"/></ce:link>
               <tgroup cols="3">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1">Compounds</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1">R</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">IC<inf loc="post">50</inf> ± SD (μM)<cross-ref refid="tbl1fna" id="crosref0190">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">HCT-116</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">1</inf> = p-CH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.74 ± 0.96</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">1</inf> = o-CF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.48 ± 0.56</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">1</inf> = m-CF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.98 ± 0.61</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">1</inf> = p-CF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.44 ± 0.49</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">1</inf> = o-F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12.67 ± 2.43</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">1</inf> = m-F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.34 ± 0.47</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">1</inf> = p-F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">14.22 ± 1.77</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">1</inf> = o,p-F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12.73 ± 1.62</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">1</inf> = m,p-F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.72 ± 0.64</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">1</inf> = o,o',m,m'p-F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.66 ± 0.51</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">1</inf> = o-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">11.06 ± 0.84</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">1</inf> = m-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.85 ± 0.56</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">1</inf> = p-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">18.22 ± 2.95</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">1</inf> = m-Br</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">23.02 ± 2.63</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">17.36 ± 2.36</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">18</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">2</inf> = m,m'-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">35.06 ± 3.92</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">2</inf> = m-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">20.58 ± 2.46</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">2</inf> = p-OCH2CH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13.96 ± 1.12</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">2</inf> = m-CH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">32.54 ± 3.18</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">2</inf> = p-CH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">16.03 ± 1.65</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">2</inf> = p-CH<inf loc="post">2</inf>CH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13.97 ± 0.96</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">2</inf> = p-F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15.17 ± 2.04</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">2</inf> = p-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">14.72 ± 1.78</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">26</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">3</inf> = p-CH(CH<inf loc="post">3</inf>)<inf loc="post">2</inf> R<inf loc="post">4</inf> = m-CF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>50</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">27</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">3</inf> = p-CH(CH<inf loc="post">3</inf>)<inf loc="post">2</inf> R<inf loc="post">4</inf> = m-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>50</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">3</inf> = p-CH(CH<inf loc="post">3</inf>)<inf loc="post">2</inf> R<inf loc="post">4</inf> = m-Br</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>50</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">29</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">R<inf loc="post">3</inf> = o,o',m,m',p-F R<inf loc="post">4</inf> = p-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>50</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">36<cross-ref refid="tbl1fnb" id="crosref0195">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15.05 ± 0.81</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl1fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0010" view="all">The inhibitory effects of the compounds on the proliferation of HCT-116 cell line were determined by the MTT assay. SD: standard deviation, all experiments were independently performed at least three times.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl1fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0015" view="all">Used as a positive control.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Research paper</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523418302939-ff1b91ef1962d9c0f1403f22a5d49a4d">
                  <ce:given-name>Jianpeng</ce:given-name>
                  <ce:surname>Guo</ce:surname>
                  <ce:cross-ref refid="fn1" id="crosref0010a">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523418302939-d1cf9a947be835fd95e9f5d003e1151d">
                  <ce:given-name>Wenying</ce:given-name>
                  <ce:surname>Yu</ce:surname>
                  <ce:cross-ref refid="fn1" id="crosref0010b">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="cor2" id="crosref0010">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au3" author-id="S0223523418302939-5be36facd87d1e221d5eee5734db4b01">
                  <ce:given-name>Guiping</ce:given-name>
                  <ce:surname>Cai</ce:surname>
               </ce:author>
               <ce:author id="au4" author-id="S0223523418302939-2e90297f20cc85a4bba96283317d4b1d">
                  <ce:given-name>Wenda</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
               </ce:author>
               <ce:author id="au5" author-id="S0223523418302939-7a4d56a29ffe88d852538cc483767949">
                  <ce:given-name>Shanshan</ce:given-name>
                  <ce:surname>Li</ce:surname>
               </ce:author>
               <ce:author id="au6" author-id="S0223523418302939-6057e4b0917dfd43e6326c21189fa489">
                  <ce:given-name>Jiawen</ce:given-name>
                  <ce:surname>Zhu</ce:surname>
               </ce:author>
               <ce:author id="au7" author-id="S0223523418302939-61fec636af7345d4cf82ee563c84d6c8">
                  <ce:given-name>Dongmei</ce:given-name>
                  <ce:surname>Song</ce:surname>
               </ce:author>
               <ce:author id="au8" orcid="0000-0002-4791-8615" author-id="S0223523418302939-6dcd0171bf7f28d6f49075140d5a7fe1">
                  <ce:given-name>Lingyi</ce:given-name>
                  <ce:surname>Kong</ce:surname>
                  <ce:cross-ref refid="cor1" id="crosref0015">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523418302939-5edf27a18287dc1389970c145f061a45">
                  <ce:textfn>Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009, People's Republic of China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines</sa:organization>
                     <sa:organization>China Pharmaceutical University</sa:organization>
                     <sa:address-line>24 Tong Jia Xiang</sa:address-line>
                     <sa:city>Nanjing</sa:city>
                     <sa:postal-code>210009</sa:postal-code>
                     <sa:country>People's Republic of China</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para id="ntpara0020" view="all">Both authors contributed equally to this paper.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:date-received day="28" month="1" year="2018"/></ce:date-received>
            <ce:date-revised day="16" month="3" year="2018"/></ce:date-revised>
            <ce:date-accepted day="17" month="3" year="2018"/></ce:date-accepted>
            <ce:abstract xml:lang="en" id="abs0010" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">Persistent activated STAT3 has a striking correlation with cancer development and inhibition of STAT3 signaling pathway is a novel therapeutic way for human cancers. Among STAT family, STAT1 and STAT3 play opposite roles in tumorigenesis. However, the discovery of selective STAT3 inhibitors is still challenging to date. In this study, a series of small-molecular (MW < 500) benzensulfanilamide derivatives were designed to selectively suppress STAT3 activation for anti-cancer treatment. The most potent compound <ce:bold>11</ce:bold> inhibited both overexpressed and IL-6 induced STAT3 phosphorylation, whereas <ce:bold>11</ce:bold> displayed little effect on the phosphorylation of other STAT isoforms STAT1, STAT5, demonstrating <ce:bold>11</ce:bold> was a selective STAT3 inhibitor. Meanwhile, <ce:bold>11</ce:bold> dismissed STAT3 DNA binding activity and colony formation. In addition, <ce:bold>11</ce:bold> elevated the ROS level and induced apoptosis of cancer cells. Furthermore, <ce:bold>11</ce:bold> effectively suppressed tumor growth in an <ce:italic>in vivo</ce:italic> mouse-xenograft model.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">Compound <ce:bold>11</ce:bold> selectively inhibited STAT3 activation to exert antitumor activity.<ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text role="short" id="alttext0010">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523418302939/fx1"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords xml:lang="en" id="kwrds0010" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>Antitumor activity</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Sulfonamide</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Selectivity</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Structure-based drug design</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0030">
                  <ce:text>STAT3 phosphorylation</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0035">
                  <ce:text>Apoptosis</ce:text>
               </ce:keyword>
            </ce:keywords>
            <ce:keywords xml:lang="en" class="abr" id="kwrds0015" view="all">
               <ce:section-title id="sectitle0030">Abbreviations used</ce:section-title>
               <ce:keyword id="kwrd0040">
                  <ce:text>DMSO</ce:text>
                  <ce:keyword id="kwrd0045">
                     <ce:text>dimethyl sulfoxide</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0050">
                  <ce:text>Erk</ce:text>
                  <ce:keyword id="kwrd0055">
                     <ce:text>extracellular regulated kinase</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0060">
                  <ce:text>rt</ce:text>
                  <ce:keyword id="kwrd0065">
                     <ce:text>room temperature</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0070">
                  <ce:text>MTT</ce:text>
                  <ce:keyword id="kwrd0075">
                     <ce:text>3–4, 5-dehyl-al-2-y]-2, 5-dphnetrazolium bromide</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0080">
                  <ce:text>SH2</ce:text>
                  <ce:keyword id="kwrd0085">
                     <ce:text>Src hmology 2</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0090">
                  <ce:text>STAT</ce:text>
                  <ce:keyword id="kwrd0095">
                     <ce:text>signal transducer and activator of transcription</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0100">
                  <ce:text>ROS</ce:text>
                  <ce:keyword id="kwrd0105">
                     <ce:text>Reactive oxygen species</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0110">
                  <ce:text>PI</ce:text>
                  <ce:keyword id="kwrd0115">
                     <ce:text>propidium iodide</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0120">
                  <ce:text>TMS</ce:text>
                  <ce:keyword id="kwrd0125">
                     <ce:text>Tetramethylsilane</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0130">
                  <ce:text>GAPDH</ce:text>
                  <ce:keyword id="kwrd0135">
                     <ce:text>glyceraldehyde-3-phosphatedehydrogenase</ce:text>
                  </ce:keyword>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0035">Introduction</ce:section-title>
                  <ce:para id="p0030" view="all">Signal transducer and activator of transcription 3 (STAT3) is persistently overexpressed in various tumor cell lines and STAT3 signaling pathway is a critical cancer causing module, indicating STAT3 is an important target for anti-tumor drug design [<ce:cross-refs refid="bib1 bib2 bib3 bib4" id="crosrefs0010">1–4</ce:cross-refs>].</ce:para>
                  <ce:para id="p0035" view="all">STAT3 monomer can be phosphorylated at tyrosine residue (Tyr705) by growth factor receptor tyrosine kinases, Janus kinases, or the Src family kinases [<ce:cross-ref refid="bib5" id="crosref0020">5</ce:cross-ref>,<ce:cross-ref refid="bib6" id="crosref0025">6</ce:cross-ref>]. Two phosphorylated STAT3 form activated homo-dimeric transcription factor complex <ce:italic>via</ce:italic> a reciprocal pTyr-SH2 domain interaction. The p-STAT3 dimers would then translocate to the nucleus, bind to specific DNA fragments, induce target gene expression, and finally cause cellular anti-apoptosis, proliferation, and tumor invasion [<ce:cross-ref refid="bib5" id="crosref0030">5</ce:cross-ref>,<ce:cross-refs refid="bib7 bib8 bib9 bib10" id="crosrefs0015">7–10</ce:cross-refs>].</ce:para>
                  <ce:para id="p0040" view="all">Among STAT protein family, STAT1, STAT3 and STAT5 are correlated with tumor progression [<ce:cross-ref refid="bib11" id="crosref0035">11</ce:cross-ref>]. Opposite to carcinogenic effect of STAT3 and STAT5, STAT1 exerts anti-tumor function <ce:italic>via</ce:italic> anti-proliferative and pro-apoptotic activities in tumor cells [<ce:cross-ref refid="bib12" id="crosref0040">12</ce:cross-ref>]. A preeminent STAT3 inhibitor should inhibit STAT3 activation with good selectivity against STAT1.</ce:para>
                  <ce:para id="p0045" view="all">The crystal structure of STAT3 SH2 domain has been resolved and it has three contiguous binding subpockets for drug targeting, including pTyr705 site, Leu706 site and side pocket [<ce:cross-refs refid="bib13 bib14 bib15 bib16" id="crosrefs0020">13–16</ce:cross-refs>]. STAT3 inhibitors, directly targeting the SH2 domain, have been recently developed, including small peptides, peptidomimetics, and non-peptidic small molecules [<ce:cross-ref refid="bib4" id="crosref0045">4</ce:cross-ref>,<ce:cross-ref refid="bib17" id="crosref0050">17</ce:cross-ref>,<ce:cross-ref refid="bib18" id="crosref0055">18</ce:cross-ref>]. Compared with other inhibitors, nonpeptidic small-molecule STAT3 inhibitors with good cell permeability, high bioavailability and target specificity represent great potential to be developed as clinical agents (<ce:cross-ref refid="fig1" id="crosref0060">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>) [<ce:cross-refs refid="bib19 bib20 bib21 bib22 bib23 bib24 bib25 bib26 bib27 bib28" id="crosrefs0025">19–28</ce:cross-refs>].</ce:para>
                  <ce:para id="p0050" view="all">Most reported STAT3 inhibitors can only bind to two pockets of SH2 domain. To improve STAT3-inhibitory activity and binding affinity, only few tripedal SH2 domain inhibitors are developed as drug candidates. The most promising compound is BP-1-102 (<ce:bold>36</ce:bold>), discovered by James Turkson research group, which is entering advanced clinical trials [<ce:cross-ref refid="bib25" id="crosref0065">25</ce:cross-ref>]. Some other tripedal STAT3 inhibitors were also reported by their group [<ce:cross-refs refid="bib5 bib6 bib7" id="crosrefs0030s">5–7</ce:cross-refs>,<ce:cross-refs refid="bib23 bib24 bib25" id="crosrefs0035">23–25</ce:cross-refs>]. However, compared with STAT3 inhibitors binding to two pockets, the anti-tumor activity of <ce:bold>36</ce:bold> is moderate. Besides, STAT isoform selectivity is still poor [<ce:cross-ref refid="bib7" id="crosref0070">7</ce:cross-ref>]. Moreover, these tripedal inhibitors with high molecular weight over 500, which violates the Lipinski's rule of five, limited its drug likeness. Our group has been studying on STAT3 inhibitors for many years and made some progress in this field [<ce:cross-ref refid="bib20" id="crosref0075">20</ce:cross-ref>,<ce:cross-ref refid="bib21" id="crosref0080">21</ce:cross-ref>,<ce:cross-refs refid="bib29 bib30 bib31" id="crosrefs0040">29–31</ce:cross-refs>]. We found that STAT3 inhibitors containing sulfanilamide portion possessed excellent anti-cancer activity and STAT3 selectivity, such as LLL12 (<ce:bold>30</ce:bold>), LY-5 (<ce:bold>31</ce:bold>) and LY-17 (<ce:bold>32</ce:bold>) [<ce:cross-refs refid="bib19 bib20 bib21" id="crosrefs0045">19–21</ce:cross-refs>]. In this study, Structure-based drug design approach was used to identify a series of sulfanilamide based tripedal STAT3 inhibitors with MW < 500, which showed promising activity against cancer and better selectivity among STAT isoforms than other tripedal STAT3 inhibitors (<ce:cross-ref refid="fig2" id="crosref0085">Fig. 2</ce:cross-ref>
                     <ce:float-anchor refid="fig2"/></ce:float-anchor>).</ce:para>
               </ce:section>
               <ce:section id="sec2" role="results" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0040">Results</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0045">Design and chemistry</ce:section-title>
                     <ce:para id="p0055" view="all">According to the X-ray structure of STAT3 SH2 domain (PDB code <ce:inter-ref xlink:href="pdb:1BG1" id="intref0010" xlink:type="simple">1BG1</ce:inter-ref>), the main pTyr705 binding site is polar, the Leu706 and the side pocket sites are hydrophobic [<ce:cross-ref refid="bib32" id="crosref0090">32</ce:cross-ref>]. Based on the above structural analysis, we used a sulfanilamide fragment as a hydrogen bond receptor to form hydrogen bonding with residue Arg609 in the pTyr705 binding site, while two other nonpolar segments were designed to bind to the other two binding spots of SH2 domain. Then, only a nitrogen atom was used to connect the three moieties for targeting the three pockets respectively. The position of sulfanilamide was determined by docking experiments. As shown in <ce:cross-ref refid="fig3" id="crosref0095">Fig. 3</ce:cross-ref>
                        <ce:float-anchor refid="fig3"/></ce:float-anchor>, in comparison with <ce:italic>para-</ce:italic>position, <ce:italic>meta-</ce:italic>position was more suitable for all three pockets and the distance of hydrogen bond with Arg609 residues for binding to pTyr705 site was shorter. So we put the sulfanilamide fragment at <ce:italic>meta-</ce:italic>position to occupy the essential pTyr705 binding site. Whereas, the sulfanilamide group couldn't form a hydrogen bond at <ce:italic>ortho-</ce:italic>position.</ce:para>
                     <ce:para id="p0060" view="all">To better fitting the side pocket, we tried various nonpolar segments in side pocket yielding compounds <ce:bold>2–16</ce:bold>. In order to obtain suitable fragment for Leu706 binding site, we placed aniline derivatives in Leu706 site, which generated a series of compounds <ce:bold>18–25</ce:bold>. In addition, we synthesized compounds <ce:bold>26–29</ce:bold> whose sulfanilamide group was linked with a protective benzyl group, thus the hydrogen bonds between compounds and Arg609 in STAT3 protein might be destroyed. The synthetic pathways of designed compounds were described in <ce:cross-ref refid="sch1" id="crosref0100">Scheme 1</ce:cross-ref>
                        <ce:float-anchor refid="sch1"/></ce:float-anchor>.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0050">MTT assay and SAR analysis</ce:section-title>
                     <ce:para id="p0065" view="all">The <ce:italic>in vitro</ce:italic> antitumor activity of all compounds were evaluated against human colonic carcinoma HCT-116 <ce:italic>via</ce:italic> MTT assay using compound <ce:bold>36</ce:bold> as a positive control. The IC<ce:inf loc="post">50</ce:inf> values of the benzensulfanilamide derivatives on HCT-116 cell line were determined and the results were illustrated in <ce:cross-ref refid="tbl1" id="crosref0105">Table 1</ce:cross-ref>
                        <ce:float-anchor refid="tbl1"/></ce:float-anchor>. Most of these compounds showed better activity than the positive control excluding the compounds with protected sulfanilamide group. Especially, compounds <ce:bold>11</ce:bold> (IC<ce:inf loc="post">50</ce:inf> = 6.65 μM for HCT-116 cell line) displayed the most potent inhibitory activity against tumor cell proliferation among all.</ce:para>
                     <ce:para id="p0070" view="all">The SAR for the benzyl groups occupying the side pocket was summarized as follows. Substituent at the <ce:italic>meta-</ce:italic>position showed better inhibitory activity than at the <ce:italic>ortho-</ce:italic> or <ce:italic>para-</ce:italic>position, comparing compounds <ce:bold>4</ce:bold> with <ce:bold>3</ce:bold> and <ce:bold>5</ce:bold>, <ce:bold>7</ce:bold> with <ce:bold>6</ce:bold> and <ce:bold>8</ce:bold> or <ce:bold>13</ce:bold> with <ce:bold>12</ce:bold> and <ce:bold>14</ce:bold>. The stronger electron-withdrawing substitutes at <ce:italic>meta-</ce:italic>position had higher antitumor activities, such as Br < Cl < F < CF<ce:inf loc="post">3</ce:inf> for compounds <ce:bold>4</ce:bold>, <ce:bold>7</ce:bold>, <ce:bold>13</ce:bold>, <ce:bold>15</ce:bold>. Thus, compound <ce:bold>11</ce:bold> possessing perfluorobenzene was most potent among all compounds in Series A. So we chose perfluorobenzene to occupy the side pocket and further tried different aniline groups fitting to the Leu706 site to generate Series B. Compounds <ce:bold>20</ce:bold>, <ce:bold>22</ce:bold>, <ce:bold>23</ce:bold>, <ce:bold>24</ce:bold> and <ce:bold>25</ce:bold> (with substitution group at <ce:italic>para-</ce:italic>position) exhibited higher inhibitory activity than compounds <ce:bold>18</ce:bold>, <ce:bold>19</ce:bold> and <ce:bold>21</ce:bold> (with substituent at the <ce:italic>meta-</ce:italic>position), indicating the substitution group should be located at the <ce:italic>para-</ce:italic>position for the Leu706 site. There was no obvious difference between the electron-donating and electron-withdrawing substituent. No or poor affinity of compounds in Series C indicated that the free sulfanilamide group was the most vital pharmacophore for anti-cancer activity.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.3" view="all">
                     <ce:label>2.3</ce:label>
                     <ce:section-title id="sectitle0055">Molecular docking study</ce:section-title>
                     <ce:para id="p0075" view="all">To determine whether the designed compounds docked to the binding sites of the STAT3 protein, the potential binding modes of the most potent compound <ce:bold>11</ce:bold> with the STAT3 SH2 domain were predicted by docking experiments. As shown in <ce:cross-ref refid="fig4" id="crosref0110">Fig. 4</ce:cross-ref>
                        <ce:float-anchor refid="fig4"/></ce:float-anchor>, <ce:bold>11</ce:bold> was docked to the hot spots of the SH2 domain, with a binding energy of −6.9 kcal/mol. The phenylsulfonamide fragment bound to the key pY705 pocket while the perfluorobenzene fragment occupied the side pocket and the isopropyl benzene fragment sat in the Leu706 subpocket. <ce:bold>11</ce:bold> bound to STAT3 SH2 <ce:italic>via</ce:italic> a hydrogen bond interaction with Arg609 residues (distance = 2.038 Å). Overall, the docking result confirmed our design and gained further understanding of the structure-activity relationship.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.4" view="all">
                     <ce:label>2.4</ce:label>
                     <ce:section-title id="sectitle0060">Compound <ce:bold>11</ce:bold> inhibited STAT3 tyrosine phosphorylation</ce:section-title>
                     <ce:para id="p0080" view="all">To examine whether the mechanism of compound <ce:bold>11</ce:bold> is on STAT3 signaling pathway, a western blot assay was performed to investigate the expression level of phosphorylated STAT3 (p-STAT3) and total STAT3 after HCT-116 cells were incubated with <ce:bold>11</ce:bold> (4–12 μM) for 20 h. As shown in <ce:cross-ref refid="fig5" id="crosref0115">Fig. 5</ce:cross-ref>
                        <ce:float-anchor refid="fig5"/></ce:float-anchor>A, <ce:bold>11</ce:bold> markedly suppressed STAT3 phosphorylation in a dose-dependent manner with little effect on total STAT3, indicating the decrease of p-STAT3 (Y705) was not related with the reduction of total STAT3. While, <ce:bold>11</ce:bold> showed better inhibition for the phosphorylated STAT3 level than <ce:bold>36</ce:bold> at 10 μM for 20 h (<ce:cross-ref refid="fig5" id="crosref0120">Fig. 5</ce:cross-ref>B).</ce:para>
                  </ce:section>
                  <ce:section id="sec2.5" view="all">
                     <ce:label>2.5</ce:label>
                     <ce:section-title id="sectitle0065">Compound <ce:bold>11</ce:bold> inhibited interleukin-6 (IL-6) induced STAT3 phosphorylation</ce:section-title>
                     <ce:para id="p0085" view="all">IL-6, a cytokine, can induce STAT3 activation [<ce:cross-ref refid="bib33" id="crosref0125">33</ce:cross-ref>]. To determine whether compound <ce:bold>11</ce:bold> is capable of inhibiting IL-6 induced STAT3 phosphorylation, HCT-116 cells were serum starved overnight, and then were left untreated or were treated with <ce:bold>11</ce:bold> (4–12 μM). After 10 h, the level of p-STAT3 (Y705) was increased by IL-6, which could be suppressed by <ce:bold>11</ce:bold> in a dose-dependent manner (<ce:cross-ref refid="fig5" id="crosref0130">Fig. 5</ce:cross-ref>C).</ce:para>
                  </ce:section>
                  <ce:section id="sec2.6" view="all">
                     <ce:label>2.6</ce:label>
                     <ce:section-title id="sectitle0070">Compound <ce:bold>11</ce:bold> inhibited STAT3 DNA-binding activity</ce:section-title>
                     <ce:para id="p0090" view="all">To further study the inhibition of STAT3 by compound <ce:bold>11</ce:bold>, we performed electrophoretic mobility shift assay (EMSA) to examine the inhibition of STAT3:STAT3 DNA-binding activity. HCT-116 cancer cells at 50% confluence were treated with <ce:bold>11</ce:bold> (4–12 μM) or DMSO for 20 h. Then cells were harvested and nuclear extracts were obtained followed by incubating with hSIE probe, and then EMSA assay was performed. The capability of STAT3 binding DNA was significantly decreased when cells were treated with <ce:bold>11</ce:bold> (<ce:cross-ref refid="fig5" id="crosref0135">Fig. 5</ce:cross-ref>D).</ce:para>
                  </ce:section>
                  <ce:section id="sec2.7" view="all">
                     <ce:label>2.7</ce:label>
                     <ce:section-title id="sectitle0075">Selectivity of compound <ce:bold>11</ce:bold> among STAT isoforms</ce:section-title>
                     <ce:para id="p0095" view="all">To investigate the selectivity of compound <ce:bold>11</ce:bold> among STAT isoforms, we further performed western blot assays to investigate the effects of <ce:bold>11</ce:bold> on STAT1 and STAT5 phosphorylation. As shown in <ce:cross-ref refid="fig5" id="crosref0140">Figs. 5</ce:cross-ref>A, <ce:bold>11</ce:bold> had little influence on the level of p-STAT1 (Y701) and p-STAT5 (Y694). In addition, we compared <ce:bold>11</ce:bold> with <ce:bold>36</ce:bold> in STAT1 phosphorylation. HCT-116 cells were exposed to <ce:bold>11</ce:bold> and <ce:bold>36</ce:bold> respectively at 10 μM for 20 h, then were harvested and carried out by immunoblotting assay. <ce:bold>11</ce:bold> had little inhibition on STAT1 while <ce:bold>36</ce:bold> inhibited phosphorylation of STAT1 (<ce:cross-ref refid="fig5" id="crosref0145">Fig. 5</ce:cross-ref>B). All these results demonstrated that <ce:bold>11</ce:bold> was a selective STAT3 inhibitor.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.8" view="all">
                     <ce:label>2.8</ce:label>
                     <ce:section-title id="sectitle0080">Compound <ce:bold>11</ce:bold> affected the expression of STAT3 related proteins</ce:section-title>
                     <ce:para id="p0100" view="all">To investigate whether upstream kinases (such as Src) or bypass kinases (such as Erk1/2) are involved in compound <ce:bold>11</ce:bold> mediated STAT3 inactivation, we examined the effects of <ce:bold>11</ce:bold> on the phosphorylation of Src, Erk1/2 by immunoblotting analysis. The result suggested <ce:bold>11</ce:bold> had little or no effect on upstream tyrosine kinase <ce:italic>p</ce:italic>-Src and didn't inhibit <ce:italic>p</ce:italic>-Erk1/2. To further study the impact of <ce:bold>11</ce:bold> on the inhibition of STAT3, we examined the expression levels of the downstream proteins, such as Cyclin D1 and Bcl-2. As shown in <ce:cross-ref refid="fig6" id="crosref0150">Fig. 6</ce:cross-ref>
                        <ce:float-anchor refid="fig6"/></ce:float-anchor>, <ce:bold>11</ce:bold> dose-dependently suppressed the expression of Cyclin D1 and Bcl-2.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.9" view="all">
                     <ce:label>2.9</ce:label>
                     <ce:section-title id="sectitle0085">Compound <ce:bold>11</ce:bold> induced apoptosis in cancer cells</ce:section-title>
                     <ce:para id="p0105" view="all">Compound <ce:bold>11</ce:bold> could down-regulate the expression of STAT3-related protein Bcl-2, which is involved in anti-apoptosis and caspase dependent pathway [<ce:cross-ref refid="bib34" id="crosref0155">34</ce:cross-ref>]. So we speculated that the anti-tumor potency of <ce:bold>11</ce:bold> might be consistent with the induction of apoptosis. To verify this, an Annexin V/7-AAD staining assay was performed to quantify the apoptotic effect of <ce:bold>11</ce:bold> in cancer cells. As shown in <ce:cross-ref refid="fig7" id="crosref0160">Fig. 7</ce:cross-ref>
                        <ce:float-anchor refid="fig7"/></ce:float-anchor>A and B, the result showed that a large percentage of HCT-116 cells underwent dose-dependent apoptosis after <ce:bold>11</ce:bold> incubation. To further study the mechanism of <ce:bold>11</ce:bold> for cell apoptosis, we evaluated the levels of caspase-related proteins by western blots. The cleavage levels of caspase-3/7/9 were increased in a dose dependent manner treated by <ce:bold>11</ce:bold> (<ce:cross-ref refid="fig5" id="crosref0165">Fig. 5</ce:cross-ref>C).</ce:para>
                  </ce:section>
                  <ce:section id="sec2.10" view="all">
                     <ce:label>2.10</ce:label>
                     <ce:section-title id="sectitle0090">Compound <ce:bold>11</ce:bold> induced the ROS generation in cancer cells</ce:section-title>
                     <ce:para id="p0110" view="all">There is ample evidence that ROS is involved in inducing cell apoptosis [<ce:cross-ref refid="bib35" id="crosref0170">35</ce:cross-ref>]. We continued to evaluate ROS production affected by <ce:bold>11</ce:bold> in cancer cells. HCT-116 cells were treated with <ce:bold>11</ce:bold> in various concentrations for 20 h, followed by incubating with 2′,7′-dichloro-fluorescein diacetate (DCFH-DA) probe before measuring the fluorescence intensity of 2′,7′-dichloro-fluorescein (DCF) by flow cytometry. The level of ROS was increased treated with <ce:bold>11 (</ce:bold>
                        <ce:cross-ref refid="fig8" id="crosref0175">Fig. 8</ce:cross-ref>
                        <ce:float-anchor refid="fig8"/></ce:float-anchor>A and B<ce:bold>)</ce:bold>, indicating <ce:bold>11</ce:bold> induced ROS production in HCT-116 cells.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.11" view="all">
                     <ce:label>2.11</ce:label>
                     <ce:section-title id="sectitle0095">Compound <ce:bold>11</ce:bold> reduced colony formation <ce:italic>in vitro</ce:italic>
                     </ce:section-title>
                     <ce:para id="p0115" view="all">To further investigate whether compound <ce:bold>11</ce:bold> treatment might inhibit proliferation, we performed colony formation assay. We treated HCT-116 cells with <ce:bold>11</ce:bold> for 20 h. After treatment, viable cells were cultured in fresh medium without <ce:bold>11</ce:bold> for 2 weeks. As shown in <ce:cross-ref refid="fig9" id="crosref0180">Fig. 9</ce:cross-ref>
                        <ce:float-anchor refid="fig9"/></ce:float-anchor>, <ce:bold>11</ce:bold> dose-dependently inhibited the proliferation of HCT-116 cells.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.12" view="all">
                     <ce:label>2.12</ce:label>
                     <ce:section-title id="sectitle0100">In vivo study of compound <ce:bold>11</ce:bold>
                     </ce:section-title>
                     <ce:para id="p0120" view="all">A mouse-xenograft model was established to evaluate the antitumor effect of compound <ce:bold>11</ce:bold> 
                        <ce:italic>in vivo</ce:italic>. Human colon cancer HCT-116 was implanted into the hind flank of female nude mice and allowed to establish sizeable tumor. After the solid tumors development, the mice were randomized and divided into three groups consisting of 6 mice/group. As shown in <ce:cross-ref refid="fig10" id="crosref0185">Fig. 10</ce:cross-ref>
                        <ce:float-anchor refid="fig10"/></ce:float-anchor>, <ce:bold>11</ce:bold> dramatically inhibited tumor weight (41.30% decrease at 10 mg/kg, 56.84% decrease at 20 mg/kg) and volume (35.69% decrease at 10 mg/kg, 58.12% decrease at 20 mg/kg). Western blot results showed that <ce:bold>11</ce:bold> inhibited the level of p-STAT3 in tumor tissue <ce:italic>in vivo</ce:italic>. There is no significant change in body weight, indicating <ce:bold>11</ce:bold> showed no obvious signs of toxicity. Moreover, we performed acute toxicity test on ICR mice to further evaluate the safety profile of <ce:bold>11</ce:bold>. No sign of toxicity was observed even at 80 mg/kg dose.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0105">Conclusions</ce:section-title>
                  <ce:para id="p0125" view="all">Taken together, a series of benzensulfanilamide derivatives were designed and synthesized as novel STAT3 inhibitors that exhibit promising antitumor activity <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic>. Our designed compounds were characterized as lower molecular weight (less than 500) and better selectivity, indicating improved drug likeness comparing to the known tripedal STAT3 inhibitors, represented by the most potent compound <ce:bold>11</ce:bold>. Molecular docking studies demonstrated <ce:bold>11</ce:bold> could tightly bind to STAT3 SH2 domain and further provided a rationale for structure-activity relationship. <ce:bold>11</ce:bold> inhibited STAT3 phosphorylation, IL-6 induced STAT3 phosphorylation, STAT3 binding activity and the expression of downstream proteins while had little impact on the phosphorylation of other STAT isoforms (STAT1, STAT5) and upstream kinase (Src). <ce:bold>11</ce:bold> inhibited the colony formation of cancer cells and induced the apoptosis. Furthermore, <ce:bold>11</ce:bold> significantly suppressed human colon cancer HCT-116 xenograft tumor growth <ce:italic>in vivo</ce:italic>. On the basic of our findings, the antiproliferative and proapoptotic effects of <ce:bold>11</ce:bold> is owning to its ability to inhibit STAT3 phosphorylation. In summary, <ce:bold>11</ce:bold> possessed good selectivity on p-STAT3 among other STAT isoforms and potent anti-tumor activity, which might be a potential antitumor drug.</ce:para>
               </ce:section>
               <ce:section id="sec4" role="materials-methods" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0110">Materials and methods</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0115">Chemistry</ce:section-title>
                     <ce:para id="p0130" view="all">The solvents and reagents were purchased from commercial suppliers and used without further purification. Reaction progress was monitored using analytical thin layer chromatography (TLC) on precoated silica gel GF254 plates (Qingdao Haiyang Chemical Plant, Qingdao, China) plates and the spots were detected under UV light (254 nm). Column chromatography was performed on silica gel (90–150 μM; Qingdao Marine Chemical Inc.) Melting points were measured on an XT-4 micromelting point instrument and uncorrected. <ce:sup loc="pre">1</ce:sup>H NMR and <ce:sup loc="pre">13</ce:sup>C NMR spectra were measured on a Bruker ACF-500 spectrometer at 25 °C and referenced to TMS. Chemical shifts are reported in ppm (<ce:italic>δ</ce:italic>) using the residual solvent line as internal standard. Mass spectra were obtained on a MS Agilent 1l00 Series LC/MSD Trap mass spectrometer (ESI-MS) and a Mariner ESI-TOF spectrometer (HRESI-MS), respectively. All of the synthetic derivatives and compounds purchased were obtained with >96.0% purity as determined by HPLC (UV detection at 280 nm).</ce:para>
                     <ce:section id="sec4.1.1" view="all">
                        <ce:label>4.1.1</ce:label>
                        <ce:section-title id="sectitle0120">General procedure for the synthesis of <ce:bold>1</ce:bold> and <ce:bold>17</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0135" view="all">To a solution of 3-aminobenzenesulfonamide (1.0 equiv) and acetic acid (1.2 equiv) stirred in anhydrous dichloromethane (0.1 M) with 4 Å molecular sieves was added aldehyde (1.2 equiv). The solution was then stirred for 30 min. Next, Na(OAc)<ce:inf loc="post">3</ce:inf>BH<ce:inf loc="post">3</ce:inf> (2.0 equiv) was added in portions and then reaction allowed to stir at room temperature overnight. When TLC indicated the reaction was complete, the reaction was filtered and the solution was concentrated, loaded on silica gel, and purified by flash column chromatography with petroleum/ethyl acetate as eluent to give <ce:bold>1</ce:bold> and <ce:bold>17</ce:bold>.</ce:para>
                        <ce:section id="sec4.1.1.1" view="all">
                           <ce:label>4.1.1.1</ce:label>
                           <ce:section-title id="sectitle0125">3-((4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>1</ce:bold>)</ce:section-title>
                           <ce:para id="p0140" view="all">Yield 96%, white solid, <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 7.27 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 2H), 7.24–7.15 (m, 5H), 7.08 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.96 (dt, <ce:italic>J</ce:italic> = 7.9, 1.0 Hz, 1H), 6.74–6.70 (m, 1H), 6.68 (t, <ce:italic>J</ce:italic> = 6.0 Hz, 1H), 4.25 (d, <ce:italic>J</ce:italic> = 5.9 Hz, 2H), 2.86 (hept, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 1.18 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 6H).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.1.2" view="all">
                           <ce:label>4.1.1.2</ce:label>
                           <ce:section-title id="sectitle0130">3-(((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>17</ce:bold>)</ce:section-title>
                           <ce:para id="p0145" view="all">Yield 94%, white solid, <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 7.54 (dd, <ce:italic>J</ce:italic> = 2.1, 1.0 Hz, 1H), 7.43 (s, 1H), 7.28 (t, <ce:italic>J</ce:italic> = 6.0 Hz, 1H), 7.17 (s, 2H), 7.03 (dd, <ce:italic>J</ce:italic> = 7.6, 2.1 Hz, 1H), 6.81 (dd, <ce:italic>J</ce:italic> = 7.6, 1.0 Hz, 1H), 4.40 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 2H).</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.2" view="all">
                        <ce:label>4.1.2</ce:label>
                        <ce:section-title id="sectitle0135">General procedure for the synthesis of <ce:bold>2</ce:bold>–<ce:bold>16</ce:bold> and <ce:bold>18</ce:bold>–<ce:bold>25</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0150" view="all">A mixture of <ce:bold>1</ce:bold> or <ce:bold>17</ce:bold> (1.0 equiv) and K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (1.5 equiv) in acetonitrile (0.1 M) was stirred at room temperature for 30 min. The benzyl halide (1.2 equiv) was added and the mixture was stirred and refluxed for 8 h. After the mixture was cooled, the inorganic salts was filtered and washed with dichloromethane. The filtrate was evaporated and the residue was purified by flash column chromatography (petroleum/ethyl acetate) to give the title compounds <ce:bold>2–16</ce:bold> and <ce:bold>18–25</ce:bold>.</ce:para>
                        <ce:section id="sec4.1.2.1" view="all">
                           <ce:label>4.1.2.1</ce:label>
                           <ce:section-title id="sectitle0140">3-((4-isopropylbenzyl) (4-methylbenzyl)amino)benzenesulfonamide(<ce:bold>2</ce:bold>)</ce:section-title>
                           <ce:para id="p0155" view="all">Yield 56%, white solid, m.p. 189–190 °C; IR (KBr) <ce:italic>ν</ce:italic> 3333.93, 3259.00, 2961.34, 2920.84, 1599.14, 1512.37, 1493.33, 1452.19, 1417.10, 1385.75, 1326.78, 1260.54, 1238.55, 1184.17, 1103.51, 1055.64, 1016.74, 987.96, 970.11, 938.99, 893.50, 850.33, 795.87, 704.34, 625.79, 547.94, 513.56, 479.79; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 7.26–7.11 (m, 12H), 7.03 (dd, <ce:italic>J</ce:italic> = 7.4, 1.5 Hz, 1H), 6.79 (dd, <ce:italic>J</ce:italic> = 8.3, 2.7 Hz, 1H), 4.66 (s, 2H), 4.65 (s, 2H), 2.85 (hept, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 2.27 (s, 3H), 1.18 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 149.05, 147.47, 145.45, 136.42, 135.95, 135.48, 129.92, 129.64, 127.07, 127.04, 126.99, 115.51, 113.28, 109.08, 53.88, 33.55, 24.39, 21.14; HRMS (ESI) <ce:italic>m/z</ce:italic> 409.1946 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 409.1944, C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">29</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.2" view="all">
                           <ce:label>4.1.2.2</ce:label>
                           <ce:section-title id="sectitle0145">3-((4-isopropylbenzyl) (2-(trifluoromethyl)benzyl)amino)benzenesulfonamide (<ce:bold>3</ce:bold>)</ce:section-title>
                           <ce:para id="p0160" view="all">Yield 44%, white solid, m.p. 112–113 °C; IR (KBr) <ce:italic>ν</ce:italic> 3425.06, 3285.04, 2965.34, 2867.99, 1603.55, 1516.56, 1487.96, 1454.12, 1419.27, 1383.28, 1320.38, 1269.74, 1161.24, 1117.55, 1082.42, 1039.88, 1016.85, 982.27, 959.96, 886.95, 874.73, 860.68, 819.11, 772.39, 698.61, 654.10, 623.01, 585.30, 513.31; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 8.14 (t, <ce:italic>J</ce:italic> = 6.2 Hz, 1H), 7.67 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H), 7.62 (s, 2H), 7.46 (dt, <ce:italic>J</ce:italic> = 8.5, 7.6 Hz, 1H), 7.27 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 2H), 7.23 (t, <ce:italic>J</ce:italic> = 7.7 Hz, 1H), 7.18 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.02 (s, 1H), 6.92 (dd, <ce:italic>J</ce:italic> = 7.6, 1.6 Hz, 1H), 6.79 (dd, <ce:italic>J</ce:italic> = 8.2, 1.6 Hz, 1H), 6.75 (t, <ce:italic>J</ce:italic> = 6.0 Hz, 1H), 4.24 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 2H), 4.07 (d, <ce:italic>J</ce:italic> = 6.2 Hz, 2H), 2.83 (hept, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 1.18 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 149.63, 147.39, 141.30, 137.20, 136.69, 133.00, 130.11, 128.15, 127.73, 126.72, 116.23, 113.59, 109.89, 46.47, 42.86, 42.84, 33.55, 24.35; HRMS (ESI) <ce:italic>m/z</ce:italic> 463.1661 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 463.1662, C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">26</ce:inf>F<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.3" view="all">
                           <ce:label>4.1.2.3</ce:label>
                           <ce:section-title id="sectitle0150">3-((4-isopropylbenzyl) (3-(trifluoromethyl)benzyl)amino)benzenesulfonamide (<ce:bold>4</ce:bold>)</ce:section-title>
                           <ce:para id="p0165" view="all">Yield 62%, white solid, m.p. 102–104 °C; IR (KBr) <ce:italic>ν</ce:italic> 3388.01, 3273.78, 2961.51, 2926.38, 2871.05, 1598.83, 1495.34, 1447.88, 1385.75, 1329.47, 1236.29, 1163.49, 1124.74, 1072.99, 1017.81, 987.45, 962.28, 896.47, 795.82, 774.64, 701.41, 588.85, 546.90, 503.85; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 7.65–7.51 (m, 4H), 7.27 (t, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 7.24–7.14 (m, 7H), 7.07 (dd, <ce:italic>J</ce:italic> = 7.6, 1.5 Hz, 1H), 6.84 (dd, <ce:italic>J</ce:italic> = 8.4, 2.6 Hz, 1H), 4.81 (s, 2H), 4.73 (s, 2H), 2.86 (hept, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 1.18 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 148.79, 147.56, 145.57, 140.50, 135.81, 131.08, 130.10, 130.06, 127.17, 126.99, 124.18, 124.15, 123.67, 115.54, 113.65, 109.09, 54.02, 53.87, 33.56, 24.37; HRMS (ESI) <ce:italic>m/z</ce:italic> 485.1485 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 485.1481, C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">25</ce:inf>F<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.4" view="all">
                           <ce:label>4.1.2.4</ce:label>
                           <ce:section-title id="sectitle0155">3-((4-isopropylbenzyl) (4-(trifluoromethyl)benzyl)amino)benzenesulfonamide (<ce:bold>5</ce:bold>)</ce:section-title>
                           <ce:para id="p0170" view="all">Yield 46%, white solid, m.p. 96–97 °C; IR (KBr) <ce:italic>ν</ce:italic> 3388.01, 3273.78, 2961.51, 2926.38, 2871.05, 1598.83, 1495.34, 1447.88, 1385.75, 1329.47, 1236.29, 1163.49, 1124.74, 1072.99, 1017.81, 987.45, 962.28, 896.47, 795.82, 774.64, 701.41, 588.85, 546.90, 503.85; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 8.10 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 1H), 7.64 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 7.44 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 7.28 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 2H), 7.24–7.15 (m, 3H), 7.00 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.92 (dt, <ce:italic>J</ce:italic> = 7.8, 1.1 Hz, 1H), 6.83–6.73 (m, 1H), 6.74 (t, <ce:italic>J</ce:italic> = 5.9 Hz, 1H), 4.25 (d, <ce:italic>J</ce:italic> = 5.9 Hz, 2H), 3.98 (d, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 2.83 (hept, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 1.15 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 149.57, 147.41, 143.35, 141.51, 137.24, 130.07, 128.64, 127.75, 126.73, 125.54, 125.51, 125.48, 125.45, 116.13, 113.60, 109.93, 46.47, 46.05, 33.55, 24.36; HRMS (ESI) <ce:italic>m/z</ce:italic> 485.1477 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 485.1481, C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">25</ce:inf>F<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.5" view="all">
                           <ce:label>4.1.2.5</ce:label>
                           <ce:section-title id="sectitle0160">3-((2-fluorobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>6</ce:bold>)</ce:section-title>
                           <ce:para id="p0175" view="all">Yield 38%, white solid; m.p. 125–126 °C; IR (KBr) <ce:italic>ν</ce:italic> 3346.44, 3268.92, 3061.77, 2961.03, 2924.42, 2871.44, 1600.30, 1497.04, 1453.76, 1431.30, 1387.47, 1360.45, 1307.61, 1268.69, 1238.66, 1221.72, 1168.99, 1094.79, 1048.98, 1015.17, 918.23, 841.10, 819.15, 773.27, 757.16, 690.76, 595.18, 523.60; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 7.35–7.29 (m, 1H), 7.27 (t, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 7.25–7.12 (m, 10H), 7.08 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 1H), 6.84 (dd, <ce:italic>J</ce:italic> = 8.4, 2.6 Hz, 1H), 4.75 (s, 2H), 4.70 (s, 2H), 2.86 (hept, <ce:italic>J</ce:italic> = 7.0 Hz, 1H), 1.18 (d, <ce:italic>J</ce:italic> = 7.0 Hz, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 161.87, 159.93, 148.76, 147.50, 145.55, 135.80, 130.01, 129.45, 128.78, 127.05, 127.01, 125.21, 124.98, 124.95, 116.02, 115.86, 115.52, 113.63, 109.11, 53.83, 48.50, 33.56, 24.38; HRMS (ESI) <ce:italic>m/z</ce:italic> 435.1510 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 435.1513, C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">25</ce:inf>FN<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.6" view="all">
                           <ce:label>4.1.2.6</ce:label>
                           <ce:section-title id="sectitle0165">3-((3-fluorobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>7</ce:bold>)</ce:section-title>
                           <ce:para id="p0180" view="all">Yield 61%, white solid, m.p. 93–94 °C; IR (KBr) <ce:italic>ν</ce:italic> 3416.29, 3279.75, 2962.04, 2927.06, 1602.10, 1518.03, 1489.23, 1449.66, 1422.08, 1315.49, 1280.40, 1254.98, 1174.62, 1152.72, 1104.28, 1082.54, 1040.74, 1018.39, 984.83, 925.56, 886.24, 841.87, 779.58, 751.75, 710.89, 626.73, 580.82, 546.13, 520.14, 501.54; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 8.02 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 1H), 7.32 (td, <ce:italic>J</ce:italic> = 7.9, 6.1 Hz, 1H), 7.27 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 7.24–7.14 (m, 4H), 7.08–6.98 (m, 5H), 6.92 (dd, <ce:italic>J</ce:italic> = 7.5, 1.7 Hz, 1H), 6.78 (dd, <ce:italic>J</ce:italic> = 8.2, 2.3 Hz, 1H), 4.24 (s, 2H), 3.91 (s, 2H), 2.83 (hept, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 1.16 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 163.32, 161.38, 149.85, 147.35, 139.85, 137.04, 130.45, 127.63, 126.73, 124.64, 124.62, 117.24, 115.31, 115.14, 114.62, 114.45, 113.97, 109.84, 51.84, 46.41, 33.50, 24.29; HRMS (ESI) <ce:italic>m/z</ce:italic> 435.1512 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 435.1513, C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">25</ce:inf>FN<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.7" view="all">
                           <ce:label>4.1.2.7</ce:label>
                           <ce:section-title id="sectitle0170">3-((4-fluorobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>8</ce:bold>)</ce:section-title>
                           <ce:para id="p0185" view="all">Yield 47%, white solid, m.p. 108–109 °C; IR (KBr) <ce:italic>ν</ce:italic> 3415.68, 3278.04, 3025.26, 2963.74, 2927.26, 2873.33, 1926.62, 1891.19, 1602.49, 1514.60, 1477.13, 1448.96, 1340.28, 1315.12, 1279.53, 1225.94, 1175.55, 1084.75, 1061.03, 1035.62, 1016.11, 889.91, 826.51, 812.16, 704.25, 675.10, 603.81; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 7.96 (td, <ce:italic>J</ce:italic> = 6.4, 2.1 Hz, 1H), 7.28 (d, <ce:italic>J</ce:italic> = 6.6 Hz, 2H), 7.25–7.29 (m, 5H), 7.09 (td, <ce:italic>J</ce:italic> = 8.9, 2.2 Hz, 2H), 7.00 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.91 (d, <ce:italic>J</ce:italic> = 7.3 Hz, 1H), 6.78 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H), 6.73 (td, <ce:italic>J</ce:italic> = 6.1, 2.0 Hz, 1H), 4.25 (d, <ce:italic>J</ce:italic> = 4.1 Hz, 2H), 3.86 (d, <ce:italic>J</ce:italic> = 6.1 Hz, 2H), 2.83 (hept, <ce:italic>J</ce:italic> = 7.0 Hz, 1H), 1.15 (d, <ce:italic>J</ce:italic> = 7.0 Hz, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 162.73, 160.80, 149.54, 147.40, 141.62, 137.25, 134.57, 134.55, 130.03, 129.97, 127.76, 126.74, 116.07, 115.45, 115.28, 113.62, 109.97, 46.48, 45.85, 33.56, 24.37; HRMS (ESI) <ce:italic>m/z</ce:italic> 435.1507 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 435.1513, C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">25</ce:inf>FN<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.8" view="all">
                           <ce:label>4.1.2.8</ce:label>
                           <ce:section-title id="sectitle0175">3-((2,3-difluorobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>9</ce:bold>)</ce:section-title>
                           <ce:para id="p0190" view="all">Yield 37%, white solid, m.p. 121–122 °C; IR (KBr) <ce:italic>ν</ce:italic> 3343.14, 3265.17, 3065.68, 2962.40, 2927.67, 2872.31, 1598.38, 1497.59, 1419.90, 1390.01, 1367.78, 1310.86, 1272.25, 1234.79, 1169.88, 1134.60, 1089.04, 1050.88, 1016.30, 989.41, 968.10, 913.29, 858.99, 820.59, 774.04, 723.27, 694.48, 596.43, 521.45; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 7.30–7.16 (m, 10H), 7.10 (dd, <ce:italic>J</ce:italic> = 7.5, 1.5 Hz, 1H), 7.04 (td, <ce:italic>J</ce:italic> = 8.5, 2.5 Hz, 1H), 6.86 (dd, <ce:italic>J</ce:italic> = 8.4, 2.6 Hz, 1H), 4.73 (s, 2H), 4.69 (s, 2H), 2.86 (hept, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 1.18 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 148.67, 147.52, 145.58, 135.75, 130.04, 127.06, 126.99, 121.54, 121.45, 115.63, 113.76, 111.96, 111.80, 109.22, 104.80, 104.59, 104.39, 53.81, 48.19, 33.56, 24.37; HRMS (ESI) <ce:italic>m/z</ce:italic> 453.1415 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 453.1419, C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">24</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.9" view="all">
                           <ce:label>4.1.2.9</ce:label>
                           <ce:section-title id="sectitle0180">3-((3,4-difluorobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>10</ce:bold>)</ce:section-title>
                           <ce:para id="p0195" view="all">Yield 36%, white solid, m.p. 116–117 °C; IR (KBr) <ce:italic>ν</ce:italic> 3344.74, 3266.08, 3064.87, 2958.79, 2925.84, 2869.47, 2318.18, 1599.62, 1518.04, 1497.08, 1431.44, 1394.99, 1310.05, 1280.92, 1236.08, 1166.11, 1105.73, 1060.37, 1015.68, 988.99, 960.81, 849.56, 819.25, 780.88, 698.33, 597.54, 519.51; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 7.39 (dt, <ce:italic>J</ce:italic> = 8.4, 7.9 Hz, 1H), 7.27 (t, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 7.24–7.18 (m, 5H), 7.16 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 2H), 7.08 (t, <ce:italic>J</ce:italic> = 7.0 Hz, 2H), 6.83 (dd, <ce:italic>J</ce:italic> = 8.4, 2.6 Hz, 1H), 4.66 (s, 2H), 4.74 (s, 2H), 2.86 (hept, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 1.18 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 148.66, 147.56, 145.54, 135.82, 130.04, 123.65, 123.62, 123.60, 123.57, 118.14, 118.01, 116.13, 115.99, 115.62, 113.66, 109.18, 53.99, 53.32, 33.57, 24.38; HRMS (ESI) <ce:italic>m/z</ce:italic> 453.1421 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 453.1419, C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">24</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.10" view="all">
                           <ce:label>4.1.2.10</ce:label>
                           <ce:section-title id="sectitle0185">3-((4-isopropylbenzyl) ((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>11</ce:bold>)</ce:section-title>
                           <ce:para id="p0200" view="all">Yield 73%, white solid, m.p. 123–124 °C; IR (KBr) <ce:italic>ν</ce:italic> 3425.19, 3284.35, 2965.16, 1599.95, 1526.43, 1499.74, 1397.54, 1360.61, 1328.76, 1230.73, 1159.74, 1120.64, 1052.88, 996.55, 965.14, 947.45, 933.18, 917.98, 774.96, 686.27, 600.15, 507.59; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 7.36–7.30 (m, 2H), 7.23 (s, 2H), 7.16–7.11 (m, 3H), 7.09 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 7.04 (dd, <ce:italic>J</ce:italic> = 8.4, 2.7 Hz, 1H), 4.84 (s, 2H), 4.59 (s, 2H), 2.83 (hept, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 1.16 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 148.60, 147.52, 145.56, 135.75, 130.09, 127.02, 126.72, 116.59, 114.60, 110.29, 53.84, 43.50, 33.53, 24.30; HRMS (ESI) <ce:italic>m/z</ce:italic> 507.1134 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 507.1136, C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">21</ce:inf>F<ce:inf loc="post">5</ce:inf>N<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.11" view="all">
                           <ce:label>4.1.2.11</ce:label>
                           <ce:section-title id="sectitle0190">3-((2-chlorobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>12</ce:bold>)</ce:section-title>
                           <ce:para id="p0205" view="all">Yield 34%, white solid, m.p. 108–109 °C; IR (KBr) <ce:italic>ν</ce:italic>3429.57, 3292.07, 3064.65, 3005.45, 2927.29, 1904.46, 1793.36, 1601.06, 1576.41, 1509.75, 1490.39, 1462.34, 1444.34, 1421.27, 1381.24, 1358.70, 1317.16, 1268.12, 1197.49, 1014.81, 996.83, 986.35, 881.85, 852.21 792.31, 777.85, 685.85, 634.87, 591.19, 522.02; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 8.03 (td, <ce:italic>J</ce:italic> = 6.3, 1.8 Hz, 1H), 7.40 (tt, <ce:italic>J</ce:italic> = 4.8, 2.4 Hz, 2H), 7.28 (ddt, <ce:italic>J</ce:italic> = 8.0, 6.3, 1.8 Hz, 4H), 7.23 (td, <ce:italic>J</ce:italic> = 8.0, 1.6 Hz, 1H), 7.20–7.16 (m, 2H), 7.03 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 6.94 (d, <ce:italic>J</ce:italic> = 7.1 Hz, 1H), 6.79 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 6.77–6.71 (m, 1H), 4.25 (d, <ce:italic>J</ce:italic> = 5.8 Hz, 2H), 3.96 (d, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 2.83 (hept, <ce:italic>J</ce:italic> = 7.0 Hz, 1H), 1.15 (d, <ce:italic>J</ce:italic> = 7.0 Hz, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 149.58, 147.39, 141.37, 137.23, 135.57, 132.49, 130.11, 130.08, 129.50, 129.42, 127.75, 127.57, 126.74, 116.19, 113.64, 109.94, 46.48, 44.06, 33.56, 24.37; HRMS (ESI) <ce:italic>m/z</ce:italic> 451.1212 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 451.1217, C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">25</ce:inf>ClN<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.12" view="all">
                           <ce:label>4.1.2.12</ce:label>
                           <ce:section-title id="sectitle0195">3-((3-chlorobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>13</ce:bold>)</ce:section-title>
                           <ce:para id="p0210" view="all">Yield 53%, white solid, m.p. 125–126 °C; IR (KBr) <ce:italic>ν</ce:italic> 3421.14, 3255.51, 3050.56, 2960.60, 2924.63, 2866.33, 1600.78, 1575.97, 1491.06, 1421.70, 1268.96, 1203.80, 1173.33, 1038.72, 1017.78, 986.71, 883.95, 869.09, 858.25, 703.22, 680.01, 626.38, 593.12, 580.14, 503.43; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 8.03 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 1H), 7.33–7.25 (m, 5H), 7.24–7.16 (m, 4H), 7.00 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.94–6.90 (m, 1H), 6.78 (ddd, <ce:italic>J</ce:italic> = 8.3, 2.5, 1.0 Hz, 1H), 6.72 (t, <ce:italic>J</ce:italic> = 5.9 Hz, 1H), 4.25 (d, <ce:italic>J</ce:italic> = 5.9 Hz, 2H), 3.90 (d, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 2.84 (hept, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 1.16 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 149.58, 147.40, 141.57, 141.05, 137.22, 133.34, 130.51, 130.05, 127.76, 127.74, 127.46, 126.74, 126.60, 116.17, 113.59, 109.87, 46.49, 45.88, 33.56, 24.38; HRMS (ESI) <ce:italic>m/z</ce:italic> 451.1216 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 451.1217, C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">25</ce:inf>ClN<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.13" view="all">
                           <ce:label>4.1.2.13</ce:label>
                           <ce:section-title id="sectitle0200">3-((4-chlorobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>14</ce:bold>)</ce:section-title>
                           <ce:para id="p0215" view="all">Yield 42%, white solid, m.p. 147–148 °C; IR (KBr) <ce:italic>ν</ce:italic> 3415.56, 3275.55, 2961.39, 2926.79, 1517.69, 1491.81, 1449.09, 1424.29, 1316.03, 1279.31, 1152.56, 1063.96, 1036.28, 1015.30, 984.49, 890.14, 839.81, 804.59, 778.59, 707.05, 674.96, 582.03, 545.43, 515.18; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 7.99 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 1H), 7.33 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.28 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 7.25–7.18 (m, 5H), 6.99 (t, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 6.93–6.90 (m, 1H), 6.78 (dd, <ce:italic>J</ce:italic> = 8.2, 2.3 Hz, 1H), 6.73 (t, <ce:italic>J</ce:italic> = 6.0 Hz, 1H), 4.24 (d, <ce:italic>J</ce:italic> = 5.9 Hz, 2H), 3.87 (d, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 2.83 (hept, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 1.15 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 149.55, 147.40, 141.57, 137.49, 137.24, 132.11, 130.05, 129.84, 128.58, 127.76, 126.74, 116.08, 113.61, 109.96, 46.48, 45.85, 33.56, 24.38; HRMS (ESI) <ce:italic>m/z</ce:italic> 451.1220 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 451.1217, C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">25</ce:inf>ClN<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.14" view="all">
                           <ce:label>4.1.2.14</ce:label>
                           <ce:section-title id="sectitle0205">3-((3-bromobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>15</ce:bold>)</ce:section-title>
                           <ce:para id="p0220" view="all">Yield 60%, white solid, m.p. 121–122 °C; IR (KBr) <ce:italic>ν</ce:italic> 3421.97, 3256.74, 2958.95, 2925.89, 1898.25, 1600.82, 1569.56, 1491.59, 1421.45, 1202.72, 1172.96, 1150.03, 1037.47, 986.85, 921.91, 901.00, 858.39, 812.09, 698.78, 592.39, 503.15; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 8.02 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 1H), 7.42 (dt, <ce:italic>J</ce:italic> = 7.5, 1.8 Hz, 1H), 7.39 (d, <ce:italic>J</ce:italic> = 1.6 Hz, 1H), 7.28 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 7.26–7.17 (m, 5H), 6.99 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.94–6.89 (m, 1H), 6.80–6.76 (m, 1H), 6.72 (t, <ce:italic>J</ce:italic> = 5.9 Hz, 1H), 4.24 (d, <ce:italic>J</ce:italic> = 5.9 Hz, 2H), 3.89 (d, <ce:italic>J</ce:italic> = 6.3 Hz, 2H), 2.83 (hept, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 1.15 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 149.58, 147.40, 141.56, 141.31, 137.22, 130.81, 130.63, 130.36, 130.06, 127.76, 127.00, 126.74, 121.97, 116.19, 113.58, 109.85, 46.50, 45.83, 33.56, 24.38; HRMS (ESI) <ce:italic>m/z</ce:italic> 495.0716 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 495.0712, C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">25</ce:inf>BrN<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.15" view="all">
                           <ce:label>4.1.2.15</ce:label>
                           <ce:section-title id="sectitle0210">3-((4-isopropylbenzyl) (naphthalen-1-ylmethyl)amino)benzenesulfonamide (<ce:bold>16</ce:bold>)</ce:section-title>
                           <ce:para id="p0225" view="all">Yield 46%, white solid, m.p. 107–109 °C; IR (KBr) <ce:italic>ν</ce:italic> 3405.30, 3274.73, 2957.60, 2924.58, 2867.45, 1725.35, 1600.45, 1510.57, 1466.88, 1322.81, 1155.46, 1083.75, 1056.93, 1017.97, 985.12, 774.48, 684.04; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 8.06–8.02 (m, 1H), 7.97–7.91 (m, 2H), 7.86 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.56–7.52 (m, 2H), 7.44–7.37 (m, 2H), 7.30 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 7.26 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.18 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 7.10 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 7.03–6.99 (m, 1H), 6.85–6.82 (m, 1H), 6.76 (t, <ce:italic>J</ce:italic> = 5.9 Hz, 1H), 4.29 (d, <ce:italic>J</ce:italic> = 6.2 Hz, 2H), 4.27 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 2H), 2.80 (hept, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 1.12 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (151 MHz, DMSO) <ce:italic>δ</ce:italic> 149.56, 147.37, 141.25, 137.22, 133.72, 133.26, 131.35, 130.12, 128.92, 128.60, 127.72, 127.08, 126.73, 126.70, 126.29, 125.74, 124.04, 116.26, 113.76, 110.01, 46.44, 44.96, 33.50, 24.31; HRMS (ESI) <ce:italic>m/z</ce:italic> 467.1761 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 467.1764, C<ce:inf loc="post">27</ce:inf>H<ce:inf loc="post">28</ce:inf>ClN<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.16" view="all">
                           <ce:label>4.1.2.16</ce:label>
                           <ce:section-title id="sectitle0215">3-((3,5-dimethoxybenzyl) ((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>18</ce:bold>)</ce:section-title>
                           <ce:para id="p0230" view="all">Yield 31%, white solid, m.p. 115–117 °C; IR (KBr) <ce:italic>ν</ce:italic> 3383.95, 3268.16, 1599.51, 1521.07, 1494.63, 1395.06, 1357.19, 1327.10, 1263.16, 1227.12, 1161.63, 1115.17, 1047.54, 996.11, 940.64, 779.01, 741.05, 687.44, 609.07, 496.66; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 7.96 (t, <ce:italic>J</ce:italic> = 6.3 Hz, 1H), 7.29 (t, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 7.08 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 7.01 (m, 1H), 6.86 (m, 1H), 6.68 (t, <ce:italic>J</ce:italic> = 6.0 Hz, 1H), 6.36 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 2H), 6.32 (t, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 4.40 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 2H), 3.92 (d, <ce:italic>J</ce:italic> = 6.3 Hz, 2H), 3.66 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (151 MHz, DMSO) <ce:italic>δ</ce:italic> 160.74, 148.50, 142.04, 140.58, 130.32, 115.91, 114.56, 109.75, 105.60, 99.43, 55.48, 46.61, 35.08; HRMS (ESI) <ce:italic>m/z</ce:italic> 451.1212 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 451.1217, C<ce:inf loc="post">23</ce:inf>H<ce:inf loc="post">25</ce:inf>ClN<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S). HRMS (ESI) <ce:italic>m/z</ce:italic> 525.0881 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 525.0878, C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">19</ce:inf>F<ce:inf loc="post">5</ce:inf>N<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">4</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.17" view="all">
                           <ce:label>4.1.2.17</ce:label>
                           <ce:section-title id="sectitle0220">3-((3-methoxybenzyl) ((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>19</ce:bold>)</ce:section-title>
                           <ce:para id="p0235" view="all">Yield 46%, white solid, m.p. 118–119 °C; IR (KBr) <ce:italic>ν</ce:italic> 3380.57, 3268.21, 2937.57, 1600.02, 1521.04, 1494.76, 1438.52, 1357.39, 1327.19, 1263.22, 1227.24, 1161.71, 1115.27, 1047.63, 961.01, 940.75, 918.56, 857.25, 778.98, 687.28, 609.15, 591.57; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 7.35–7.29 (m, 2H), 7.25–7.17 (m, 3H), 7.15–7.11 (m, 1H), 7.03–6.98 (m, 1H), 6.80–6.71 (m, 3H), 4.85 (s, 2H), 4.59 (s, 2H), 3.68 (s, 3H); <ce:sup loc="pre">13</ce:sup>C NMR (151 MHz, DMSO) <ce:italic>δ</ce:italic> 159.85, 148.29, 145.48, 140.06, 130.08, 130.05, 119.06, 116.59, 114.63, 112.74, 112.55, 110.28, 55.36, 53.95, 43.70; HRMS (ESI) <ce:italic>m/z</ce:italic> 495.0770 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 495.0772, C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">17</ce:inf>F<ce:inf loc="post">5</ce:inf>N<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">3</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.18" view="all">
                           <ce:label>4.1.2.18</ce:label>
                           <ce:section-title id="sectitle0225">3-((4-ethoxybenzyl) ((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>20</ce:bold>)</ce:section-title>
                           <ce:para id="p0240" view="all">Yield 43%, white solid, m.p. 101–102 °C; IR (KBr) <ce:italic>ν</ce:italic> 3431.18, 2986.73, 2870.05, 1605.64, 1509.34, 1425.84, 1332.90, 1301.23, 1257.54, 1155.28, 1120.36, 1073.77, 1049.48, 1026.04, 987.36, 955.97, 937.85, 822.52, 778.31, 686.52, 587.38, 499.82; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 8.20 (t, <ce:italic>J</ce:italic> = 5.9 Hz, 1H), 7.27–7.22 (m, 2H), 7.18 (t, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 6.89 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.88–6.84 (m, 3H), 6.74 (dd, <ce:italic>J</ce:italic> = 7.8, 2.2 Hz, 1H), 6.68 (t, <ce:italic>J</ce:italic> = 5.9 Hz, 1H), 4.18 (d, <ce:italic>J</ce:italic> = 5.8 Hz, 2H), 4.03 (d, <ce:italic>J</ce:italic> = 5.9 Hz, 2H), 3.96 (q, <ce:italic>J</ce:italic> = 6.9 Hz, 2H), 1.29 (t, <ce:italic>J</ce:italic> = 6.9 Hz, 3H); <ce:sup loc="pre">13</ce:sup>C NMR (151 MHz, DMSO) <ce:italic>δ</ce:italic> 157.94, 149.38, 141.00, 131.37, 129.83, 128.86, 116.13, 114.68, 113.43, 109.70, 63.35, 46.14, 34.28, 15.09; HRMS (ESI) <ce:italic>m/z</ce:italic> 509.0924 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 509.0929, C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">19</ce:inf>F<ce:inf loc="post">5</ce:inf>N<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">3</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.19" view="all">
                           <ce:label>4.1.2.19</ce:label>
                           <ce:section-title id="sectitle0230">3-((3-methylbenzyl) ((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>21</ce:bold>)</ce:section-title>
                           <ce:para id="p0245" view="all">Yield 35%, white solid, m.p. 135–136 °C; IR (KBr) <ce:italic>ν</ce:italic> 3451.52, 1635.29, 1507.92, 1422.79, 1331.74, 1253.14, 1157.09, 1122.82, 1076.07, 1023.84, 955.86, 937.24, 781.05, 685.31, 587.43, 501.23; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 8.25–8.18 (m, 1H), 7.23–7.15 (m, 4H), 7.12 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 1H), 7.03 (d, <ce:italic>J</ce:italic> = 7.4 Hz, 1H), 6.91 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.85 (dt, <ce:italic>J</ce:italic> = 7.9, 1.1 Hz, 1H), 6.75–6.69 (m, 2H), 4.22 (d, <ce:italic>J</ce:italic> = 5.9 Hz, 2H), 4.09–4.00 (m, 2H), 2.27 (s, 3H); <ce:sup loc="pre">13</ce:sup>C NMR (151 MHz, DMSO) <ce:italic>δ</ce:italic> 149.44, 141.06, 139.72, 137.91, 129.86, 128.72, 128.22, 127.94, 124.68, 115.97, 113.49, 109.73, 46.72, 34.26, 21.48; HRMS (ESI) <ce:italic>m/z</ce:italic> 479.0800 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 479.0796, C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">17</ce:inf>F<ce:inf loc="post">5</ce:inf>N<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.20" view="all">
                           <ce:label>4.1.2.20</ce:label>
                           <ce:section-title id="sectitle0235">3-((4-methylbenzyl) ((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>22</ce:bold>)</ce:section-title>
                           <ce:para id="p0250" view="all">Yield 46%, white solid, m.p. 150–152 °C; IR (KBr) <ce:italic>ν</ce:italic> 3512.43, 3419.92, 1604.04, 1507.98, 1421.40, 1330.97, 1159.99, 1119.81, 1025.97, 954.29, 773.97, 717.86, 589.34; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 8.21 (t, <ce:italic>J</ce:italic> = 5.9 Hz, 1H), 7.22 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 2H), 7.17 (t, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.13 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 2H), 6.89 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.86–6.83 (m, 1H), 6.74–6.69 (m, 2H), 4.21 (d, <ce:italic>J</ce:italic> = 5.9 Hz, 2H), 4.04 (d, <ce:italic>J</ce:italic> = 5.9 Hz, 2H), 2.25 (s, 3H); <ce:sup loc="pre">13</ce:sup>C NMR (151 MHz, DMSO) <ce:italic>δ</ce:italic> 149.40, 141.05, 136.67, 136.30, 129.84, 129.37, 127.56, 116.02, 113.46, 109.75, 46.43, 34.28, 21.09; HRMS (ESI) <ce:italic>m/z</ce:italic> 479.0803 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 479.0796, C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">17</ce:inf>F<ce:inf loc="post">5</ce:inf>N<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.21" view="all">
                           <ce:label>4.1.2.21</ce:label>
                           <ce:section-title id="sectitle0240">3-((4-ethylbenzyl) ((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>23</ce:bold>)</ce:section-title>
                           <ce:para id="p0255" view="all">Yield 63%, white solid, m.p. 130–131 °C; IR (KBr) <ce:italic>ν</ce:italic> 3856.29, 3451.14, 1600.23, 1527.99, 1501.18, 1361.89, 1328.62, 1157.49, 1121.20, 998.37, 777.57, 694.33, 601.29, 510.25; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 7.35–7.30 (m, 2H), 7.21 (s, 2H), 7.14–7.07 (m, 5H), 7.02 (dd, <ce:italic>J</ce:italic> = 8.4, 2.6 Hz, 1H), 4.84 (s, 2H), 4.59 (s, 2H), 2.54 (q, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 1.13 (t, <ce:italic>J</ce:italic> = 7.6 Hz, 3H); <ce:sup loc="pre">13</ce:sup>C NMR (151 MHz, DMSO) <ce:italic>δ</ce:italic> 148.41, 145.48, 142.87, 135.50, 130.07, 128.25, 127.02, 116.59, 114.55, 110.27, 53.74, 43.57, 28.24, 16.11; HRMS (ESI) <ce:italic>m/z</ce:italic> 493.0976 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 493.0980, C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">19</ce:inf>F<ce:inf loc="post">5</ce:inf>N<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.22" view="all">
                           <ce:label>4.1.2.22</ce:label>
                           <ce:section-title id="sectitle0245">3-((4-fluorobenzyl) ((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>24</ce:bold>)</ce:section-title>
                           <ce:para id="p0260" view="all">Yield 35%, white solid, m.p. 95–96 °C; IR (KBr) <ce:italic>ν</ce:italic> 3451.55, 1604.31, 1508.03, 1321.31, 1218.98, 1154.70, 1131.16, 1043.81, 974.08, 935.50, 829.50, 769.02, 681.30, 601.96; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 7.99 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 1H), 7.28 (t, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.25–7.21 (m, 2H), 7.10–7.04 (m, 3H), 6.99 (dd, <ce:italic>J</ce:italic> = 7.0, 1.4 Hz, 1H), 6.84 (dd, <ce:italic>J</ce:italic> = 8.1, 2.4 Hz, 1H), 6.65 (t, <ce:italic>J</ce:italic> = 6.1 Hz, 1H), 4.40 (d, <ce:italic>J</ce:italic> = 5.6 Hz, 2H), 3.93 (d, <ce:italic>J</ce:italic> = 6.1 Hz, 2H); <ce:sup loc="pre">13</ce:sup>C NMR (151 MHz, DMSO) <ce:italic>δ</ce:italic> 148.51, 141.89, 134.48, 130.37, 130.34, 129.96, 129.90, 115.83, 115.41, 115.27, 114.54, 109.90, 45.81, 35.10, 31.60, 30.27; HRMS (ESI) <ce:italic>m/z</ce:italic> 483.0542 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 483.0545, C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">14</ce:inf>F<ce:inf loc="post">6</ce:inf>N<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.23" view="all">
                           <ce:label>4.1.2.23</ce:label>
                           <ce:section-title id="sectitle0250">3-((4-chlorobenzyl) ((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>25</ce:bold>)</ce:section-title>
                           <ce:para id="p0265" view="all">Yield 33%, white solid, m.p. 94–96 °C; IR (KBr) <ce:italic>ν</ce:italic> 3434.34, 1605.41, 1504.27, 1304.98, 1155.42, 1032.11, 937.58, 777.90, 708.39, 587.20; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 8.04 (t, <ce:italic>J</ce:italic> = 6.3 Hz, 1H), 7.34–7.27 (m, 3H), 7.24 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.07 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 7.02–6.98 (m, 1H), 6.86 (dd, <ce:italic>J</ce:italic> = 7.9, 2.2 Hz, 1H), 6.68 (s, 1H), 4.41 (s, 2H), 3.96 (d, <ce:italic>J</ce:italic> = 6.3 Hz, 2H); <ce:sup loc="pre">13</ce:sup>C NMR (151 MHz, DMSO) <ce:italic>δ</ce:italic> 148.52, 141.84, 137.41, 132.11, 130.36, 129.76, 128.55, 115.83, 114.53, 109.88, 45.80, 35.10; HRMS (ESI) <ce:italic>m/z</ce:italic> 499.0279 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 499.0277, C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">14</ce:inf>ClF<ce:inf loc="post">5</ce:inf>N<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.3" view="all">
                        <ce:label>4.1.3</ce:label>
                        <ce:section-title id="sectitle0255">General procedure for the synthesis of <ce:bold>26</ce:bold>–<ce:bold>29</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0270" view="all">A mixture of <ce:bold>1</ce:bold> or <ce:bold>17</ce:bold> (1.0 equiv) and K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (2.0 equiv) in acetonitrile (0.1 M) was stirred at room temperature for 30 min. The benzyl halide (2.5 equiv) was added and the mixture was stirred and refluxed overnight. After the mixture was cooled, the inorganic salts was filtered and washed with dichloromethane. The filtrate was evaporated and the residue was purified by flash column chromatography (petroleum/ethyl acetate) to give the compounds <ce:bold>26–29</ce:bold>.</ce:para>
                        <ce:section id="sec4.1.3.1" view="all">
                           <ce:label>4.1.3.1</ce:label>
                           <ce:section-title id="sectitle0260">3-((4-isopropylbenzyl) (3-(trifluoromethyl)benzyl)amino)-N-(3-(trifluoromethyl)benzyl)benzenesulfonamide (<ce:bold>26</ce:bold>)</ce:section-title>
                           <ce:para id="p0275" view="all">Yield 65%, white solid, m.p. 89–91 °C; IR (KBr) <ce:italic>ν</ce:italic> 3428.23, 3397.96, 2969.09, 1600.77, 1514.89, 1474.40, 1330.49, 1278.29, 1164.05, 1125.01, 1073.62, 913.17, 860.82, 807.08, 772.80, 747.66, 700.60, 580.95, 510.26; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 7.46–7.41 (m, 2H), 7.38–7.27 (m, 7H), 7.25 (s, 2H), 7.15 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 7.06–7.03 (m, 1H), 7.03–7.00 (m, 1H), 6.95 (dd, <ce:italic>J</ce:italic> = 8.2, 2.3 Hz, 1H), 6.87 (t, <ce:italic>J</ce:italic> = 5.8 Hz, 1H), 4.31 (d, <ce:italic>J</ce:italic> = 5.8 Hz, 2H), 4.27 (s, 4H), 2.76 (p, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 1.09 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (151 MHz, DMSO) <ce:italic>δ</ce:italic> 149.87, 147.36, 139.33, 138.52, 137.02, 132.64, 130.44, 129.44, 129.35, 129.14, 127.66, 126.69, 125.27, 125.07, 125.04, 124.35, 124.32, 123.46, 117.43, 113.95, 109.76, 52.71, 46.42, 33.45, 24.20; HRMS (ESI) <ce:italic>m/z</ce:italic> 620.1906 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 620.1904, C<ce:inf loc="post">32</ce:inf>H<ce:inf loc="post">30</ce:inf>F<ce:inf loc="post">6</ce:inf>N<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.2" view="all">
                           <ce:label>4.1.3.2</ce:label>
                           <ce:section-title id="sectitle0265">N-(3-chlorobenzyl)-3-((3-chlorobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>27</ce:bold>)</ce:section-title>
                           <ce:para id="p0280" view="all">Yield 72%, white solid, m.p. 93–95 °C; IR (KBr) <ce:italic>ν</ce:italic> 3407.15, 2961.75, 2924.71, 2870.74, 2352.23, 2311.42, 1644.84, 1599.62, 1518.35, 1473.16, 1431.17, 1330.21, 1277.04, 1206.37, 1151.86, 1097.49, 1081.89, 1061.99, 1019.64, 981.93, 946.37, 923.76, 843.80, 782.26, 761.54, 701.73, 683.17, 626.70, 607.48, 582.42, 506.20, 489.18; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 7.31 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.28 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 2H), 7.23–7.17 (m, 4H), 7.15 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 7.03–6.98 (m, 5H), 6.97 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 6.93 (ddd, <ce:italic>J</ce:italic> = 8.3, 2.4, 0.9 Hz, 1H), 6.86 (t, <ce:italic>J</ce:italic> = 5.9 Hz, 1H), 4.29 (d, <ce:italic>J</ce:italic> = 5.8 Hz, 2H), 4.15 (s, 4H), 2.78 (hept, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 1.11 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 149.89, 147.37, 139.11, 137.07, 133.93, 132.79, 130.45, 130.43, 129.52, 129.43, 127.66, 127.29, 126.74, 117.27, 114.20, 110.05, 50.14, 46.45, 33.50, 24.28; HRMS (ESI) <ce:italic>m/z</ce:italic> 575.1293 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 525.1297, C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">30</ce:inf>Cl<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.3" view="all">
                           <ce:label>4.1.3.3</ce:label>
                           <ce:section-title id="sectitle0270">N-(3-bromobenzyl)-3-((3-bromobenzyl) (4-isopropylbenzyl)amino)benzenesulfonamide (<ce:bold>28</ce:bold>)</ce:section-title>
                           <ce:para id="p0285" view="all">Yield 76%, white solid, m.p. 104–106 °C; IR (KBr) <ce:italic>ν</ce:italic> 3421.87, 1604.07, 1500.87, 1330.27, 1269.34, 1155.69, 1121.13, 1086.98, 1031.79, 986.91, 915.09, 841.12, 789.88, 761.49, 684.61, 580.68, 521.84; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 7.34 (dt, <ce:italic>J</ce:italic> = 7.9, 1.1 Hz, 2H), 7.31 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.28 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 7.13 (m, 6H), 7.03 (dt, <ce:italic>J</ce:italic> = 8.0, 1.2 Hz, 2H), 7.00 (dd, <ce:italic>J</ce:italic> = 7.2, 1.2 Hz, 1H), 6.96 (d, <ce:italic>J</ce:italic> = 1.9 Hz, 1H), 6.93 (dd, <ce:italic>J</ce:italic> = 8.0, 1.9 Hz, 1H), 6.85 (t, <ce:italic>J</ce:italic> = 5.8 Hz, 1H), 4.29 (d, <ce:italic>J</ce:italic> = 5.8 Hz, 2H), 4.14 (s, 4H), 2.78 (hept, <ce:italic>J</ce:italic> = 6.9 Hz, 1H), 1.11 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 149.87, 147.35, 139.74, 139.70, 137.02, 131.35, 130.61, 130.58, 130.40, 127.66, 127.62, 126.73, 121.91, 117.38, 113.93, 109.74, 51.94, 46.45, 33.50, 24.32; HRMS (ESI) <ce:italic>m/z</ce:italic> 640.0412 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 640.0416, C<ce:inf loc="post">30</ce:inf>H<ce:inf loc="post">30</ce:inf>Br<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.4" view="all">
                           <ce:label>4.1.3.4</ce:label>
                           <ce:section-title id="sectitle0275">N-(4-chlorobenzyl)-3-((4-chlorobenzyl) ((perfluorophenyl)methyl)amino)benzenesulfonamide (<ce:bold>29</ce:bold>)</ce:section-title>
                           <ce:para id="p0290" view="all">Yield 77%, white solid, m.p. 128–129 °C; IR (KBr) <ce:italic>ν</ce:italic> 3389.11, 2958.61, 2925.44, 2870.09, 1639.83, 1599.46, 1572.77, 1515.72, 1474.91, 1426.55, 1384.22, 1325.90, 1274.44, 1201.40, 1150.45, 1096.65, 1067.67, 1019.75, 985.91, 938.80, 912.05, 874.89, 836.63, 806.85, 786.14, 755.37, 687.95, 624.20, 581.23, 542.49, 507.82, 428.69; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO-d6) <ce:italic>δ</ce:italic> 7.35 (t, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.22 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 4H), 7.11–7.06 (m, 2H), 7.03 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 4H), 6.99–6.95 (m, 1H), 6.81 (t, <ce:italic>J</ce:italic> = 6.2 Hz, 1H), 4.45 (d, <ce:italic>J</ce:italic> = 6.2 Hz, 2H), 4.22 (s, 4H); <ce:sup loc="pre">13</ce:sup>C NMR (151 MHz, DMSO) <ce:italic>δ</ce:italic> 148.79, 140.30, 135.73, 132.41, 130.70, 130.37, 128.91, 128.49, 117.22, 115.02, 113.19, 109.16, 51.17, 34.96; HRMS (ESI) <ce:italic>m/z</ce:italic> 623.0352 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 623.0357, C<ce:inf loc="post">27</ce:inf>H<ce:inf loc="post">19</ce:inf>Cl<ce:inf loc="post">2</ce:inf>F<ce:inf loc="post">5</ce:inf>N<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0280">Molecular docking studies</ce:section-title>
                     <ce:para id="p0295" view="all">Docking studies were performed with computational docking program AutoDock4.2. Compounds were docked using the Lamarckian Genetic Algorithm. The Schrodinger software was employed to prepare the macromolecule and ligand. Gasteiger charges were assigned to the ligands by AutoDockTools. AutoGrid maps were further precomputed for all atom types in the ligand set. After completing 10 million energy evaluations, the root-mean-square deviation threshold was set as 2.0 Å and all the conformations of the ligands in the binding pocket of the macromolecule were clustered. The lowest energy clusters were identified and binding energies were evaluated.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.3" view="all">
                     <ce:label>4.3</ce:label>
                     <ce:section-title id="sectitle0285">Cell line and cell culture</ce:section-title>
                     <ce:para id="p0300" view="all">Cancer cell line human colonic carcinoma HCT-116 was purchased from the Cell Bank of Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). HCT-116 cells were cultured in Dulbecco modified Eagle medium (DMEM) plus 10% (vol/vol) fetal bovine serum (FBS), 50 mg/ml penicillin and 50 mg/ml streptomycin. Both cell lines were incubated at 37 °C in a humidified atmosphere containing 5% CO<ce:inf loc="post">2</ce:inf>.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.4" view="all">
                     <ce:label>4.4</ce:label>
                     <ce:section-title id="sectitle0290">Cell viability assays</ce:section-title>
                     <ce:para id="p0305" view="all">Cells (HCT116) were seeded in 96-well plates at a density of 3500–6000 cells per well. The cells were incubated at 37 °C overnight in a humidified 5% CO<ce:inf loc="post">2</ce:inf> incubator. After medium removal, different concentrations of test compounds were added in triplicate to the plates in 200 μL fresh mediums, the plates were incubated at 37 °C for 48 h. The percentage of DMSO in the medium not exceeded 0.1% 3-(4, 5-Dimethylthiazolyl)-2, 5-diphenyltetrazoliumbromide (MTT) was added to evaluate cell viability. The absorbance was measured at 570 nm using a microplate reader (Spectramax Plus 384, Molecular Devices, Sunnyvale, CA, USA). The cytotoxic activity was expressed as the IC<ce:inf loc="post">50</ce:inf> values. All experiments were conducted in triplicate and repeated more than three times.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.5" view="all">
                     <ce:label>4.5</ce:label>
                     <ce:section-title id="sectitle0295">Western blot assays</ce:section-title>
                     <ce:para id="p0310" view="all">HCT-116 cells were incubated with various concentrations of compound <ce:bold>11</ce:bold> or 0.1% DMSO for 20 h. Harvested after trypsinisation, cells were treated with 1 × RIPA lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA and protease inhibitors PMSF) (Amresco, Solon, USA) to extract the total proteins. An aliquot of proteins from the total cell lysates (40–80 μg per lane) was separated by sodium dodecyl sulfate (8% or 10%) polyacrylamide gel electrophoresis (SDS-PAGE, BioRad Laboratories, Hercules, CA), wet-transferred to PVDF membrane (BioRad Laboratories, Hercules, CA) and blotted with primary antibodies specific for STAT1, p-STAT1 (Y701), STAT3, p-STAT3 (Y705), STAT5, p-STAT5 (Y694), Src, <ce:italic>p</ce:italic>-Src, Erk1/2, <ce:italic>p</ce:italic>-Erk1/2, Bcl-2, Cyclin D1, Caspase-3, Cleaved Caspase-3, Caspase-7, Cleaved Caspase-7, Caspase-9, Cleaved Caspase-9 and GAPDH, probed with secondary isotype specific antibodies tagged with horseradish peroxidase (Cell Signaling Technology). Bound immunocomplexes were detected using a ChemiDOC™ XRS + system (BioRad Laboratories, Hercules, CA).</ce:para>
                  </ce:section>
                  <ce:section id="sec4.6" view="all">
                     <ce:label>4.6</ce:label>
                     <ce:section-title id="sectitle0300">IL-6 induction of STAT3 phosphorylation</ce:section-title>
                     <ce:para id="p0315" view="all">HCT-116 cells were seeded in 6-well plates and allowed to adhere overnight. The following night, the cells were serum starved. The cells were then left untreated or were treated with compound <ce:bold>11</ce:bold> or DMSO. After 10 h, the untreated and <ce:bold>11</ce:bold> treated cells were stimulated by IL-6 (25 ng/ml). The cells were harvested at 30 min and analyzed by Western blot.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.7" view="all">
                     <ce:label>4.7</ce:label>
                     <ce:section-title id="sectitle0305">Nuclear extract preparation and gel shift assays</ce:section-title>
                     <ce:para id="p0320" view="all">HCT-116 cells at 45%–55% confluence were treated with compound <ce:bold>11</ce:bold> or DMSO in the presence of 10% FBS for 20 h. The cells were harvested and nuclear extract preparations and EMSA analysis were carried out as previously described. The <ce:sup loc="pre">32</ce:sup>P labeled oligonucleotide hSIE probe was used to bind STAT3.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.8" view="all">
                     <ce:label>4.8</ce:label>
                     <ce:section-title id="sectitle0310">Annexin V-APC/7-AAD double staining to detect apoptosis</ce:section-title>
                     <ce:para id="p0325" view="all">HCT-116 cells growing in the logarithmic phase were trypsinized and seeded into a 6-well plate. After attach to the plate, cells were treated with compound <ce:bold>11</ce:bold> for 20 h, 0.25% trypsin (without EDTA) was used to trypsinize and gather the cells. The cells were washed twice with phosphate-buffered saline (PBS) (centrifugation at 2000 rpm, 5 min) and collected. The cells were then resuspended in 500 μL of binding buffer. After 5 μL of Annexin V-APC was added and mixed well, 5 μL of 7-AAD was added and mixed well. After 15 min of incubation, a flow cytometer (FACSCalibur; Becton-Dickinson, USA) was used to detect apoptosis.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.9" view="all">
                     <ce:label>4.9</ce:label>
                     <ce:section-title id="sectitle0315">ROS evaluation by flow cytometry</ce:section-title>
                     <ce:para id="p0330" view="all">The level of intracellular ROS was measured by using the ROS-sensitive dye, 2′, 7′-dichloro-fluorescein diacetate (DCFH-DA), as a probe. In brief, HCT-116 cells were seeded in six-well plates at 3 × 10<ce:sup loc="post">5</ce:sup> cells/well, culturing in the presence or absence of various concentrations of compound <ce:bold>11</ce:bold> for additional 20 h, and then washed three times and incubated with final concentration of 10 μM DCFH-DA for 30 min at 37 °C in the dark. After incubation, cells were washed three times and harvested in free-serum medium. The fluorescence of 2′, 7′-dichlorofluorescein (DCF) was detected by flow cytometry (488 nm excitation and 525 nm emission filters) using BD Accuri C6 flow cytometer (Becton & Dickinson Company, Franklin Lakes, NJ, USA). Data were processed using cell quest software (Becton & Dickinson Company, Franklin Lakes, NJ).</ce:para>
                  </ce:section>
                  <ce:section id="sec4.10" view="all">
                     <ce:label>4.10</ce:label>
                     <ce:section-title id="sectitle0320">Colony survival assays</ce:section-title>
                     <ce:para id="p0335" view="all">Cells were cultured at 500 cells per well in 6-well plate with regular growth medium. Cells were treated by vehicle, and compound <ce:bold>11</ce:bold> at various concentrations on the following day for 20 h. And Cells were allowed to grow for 2 weeks until the colonies were visible. Crystal violet solution (Sigma, St. Louis, MO, USA) was used to stain the colonies for 4 h.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.11" view="all">
                     <ce:label>4.11</ce:label>
                     <ce:section-title id="sectitle0325">In vivo tumor studies</ce:section-title>
                     <ce:para id="p0340" view="all">Six-week-old female nude mice, of Specified Pathogens Free (SPF) grade, were purchased from Model Animal Research Center of Nanjing University (Nanjing, China). Nude mice were injected in the right flank area with 5 × 10<ce:sup loc="post">6</ce:sup> human colon cancer HCT-116 cells in 100 μL of PBS. After 5–10 days, tumors with a diameter of 3 mm were established. The mice were divided randomly into three groups (6 mice/group) and intraperitoneally administered with compound <ce:bold>11</ce:bold> (10 or 20 mg/kg) or vehicle daily and monitored every 2 or 3 days. Tumor growth was determined by Tumor volume, which was calculated according to formula <ce:italic>V</ce:italic> = 0.52 × <ce:italic>a</ce:italic>
                        <ce:sup loc="post">2</ce:sup> × <ce:italic>b</ce:italic> (<ce:italic>a</ce:italic> is the smallest superficial diameter and <ce:italic>b</ce:italic> is the largest superficial diameter). After 15 days of treatment, tumors were harvested from killed mice, snap-frozen in liquid nitrogen, and stored at −80 °C. Tumors tissue homogenates were lysed and separated by SDS-PAGE to examine the expression of STAT3 phosphorylation in vehicle- and <ce:bold>11</ce:bold>-treated mice.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.12" view="all">
                     <ce:label>4.12</ce:label>
                     <ce:section-title id="sectitle0330">Acute toxicity tests</ce:section-title>
                     <ce:para id="p0345" view="all">Six-week-old female mice, of Specified Pathogens Free (SPF) grade, were purchased from Qinglongshan Animal Breeding Ground (Nanjing, China). Mice were divided into four treatment (<ce:italic>i.p.</ce:italic>) groups consisting of five mice/group: 10, 20, 40 and 80 mg/kg of <ce:bold>11</ce:bold>, and the animals were observed for abnormal behavior and mortality up to 2 weeks post treatment.</ce:para>
                     <ce:para id="p0350" view="all">The experimental mice were cared and handled strictly according to obligations of the Animal Ethics Committee of China Pharmaceutical University and the National Institutes of Health (NIH) standard guidelines for the Care and Use of Laboratory Animal.</ce:para>
                  </ce:section>
               </ce:section>
            </ce:sections>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0335">Acknowledgments</ce:section-title>
               <ce:para id="p0355" view="all">This research work was supported by <ce:grant-sponsor id="gs1" sponsor-id="https://doi.org/10.13039/501100001809" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">National Natural Science Foundation of China</ce:grant-sponsor> (Grant No.<ce:grant-number refid="gs1">81673298</ce:grant-number> and No. <ce:grant-number refid="gs1">81402791</ce:grant-number>), <ce:grant-sponsor id="gs2" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Natural Science Foundation of the Jiangsu Higher Education Institutions of China</ce:grant-sponsor> (Grant No. <ce:grant-number refid="gs2">BK20140670</ce:grant-number>), Program for Changjiang Scholars and <ce:grant-sponsor id="gs3" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Innovative Research Team in University</ce:grant-sponsor> (IRT_15R63), Project Funded by the <ce:grant-sponsor id="gs4" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Priority Academic Program Development</ce:grant-sponsor> of Jiangsu Higher Education Institutions (PAPD), Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX17_0731).</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0340">Supplementary data</ce:section-title>
                  <ce:para id="p0360" view="all">The following are the supplementary data related to this article:<ce:display>
                        <ce:e-component id="mmc1">
                           <ce:label>Supporting Information</ce:label>
                           <ce:alt-text role="short" id="alttext0015">Supporting Information</ce:alt-text>
                           <ce:link locator="mmc1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:href="pii:S0223523418302939/mmc1"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                     <ce:display>
                        <ce:e-component id="mmc2">
                           <ce:label>STAT3 and ortho-substituted skeleton complex</ce:label>
                           <ce:alt-text role="short" id="alttext0020">STAT3 and ortho-substituted skeleton complex</ce:alt-text>
                           <ce:link locator="mmc2" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:href="pii:S0223523418302939/mmc2"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                     <ce:display>
                        <ce:e-component id="mmc3">
                           <ce:label>STAT3 and meta-substituted skeleton complex</ce:label>
                           <ce:alt-text role="short" id="alttext0025">STAT3 and meta-substituted skeleton complex</ce:alt-text>
                           <ce:link locator="mmc3" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:href="pii:S0223523418302939/mmc3"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                     <ce:display>
                        <ce:e-component id="mmc4">
                           <ce:label>STAT3 and para-substituted skeleton complex</ce:label>
                           <ce:alt-text role="short" id="alttext0030">STAT3 and para-substituted skeleton complex</ce:alt-text>
                           <ce:link locator="mmc4" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:href="pii:S0223523418302939/mmc4"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                     <ce:display>
                        <ce:e-component id="mmc5">
                           <ce:label>STAT3 and 11 complex</ce:label>
                           <ce:alt-text role="short" id="alttext0035">STAT3 and 11 complex</ce:alt-text>
                           <ce:link locator="mmc5" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:href="pii:S0223523418302939/mmc5"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0345">Supplementary data</ce:section-title>
                  <ce:para id="p0365" view="all">Supplementary data related to this article can be found at <ce:inter-ref xlink:href="doi:10.1016/j.ejmech.2018.03.053" id="intref0015" xlink:type="simple">https://doi.org/10.1016/j.ejmech.2018.03.053</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0350">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Miklossy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Hilliard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic modulators of STAT signalling for human diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>611</sb:first-page>
                              <sb:last-page>629</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Debnath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Neamati</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small molecule inhibitors of signal transducer and activator of transcription 3 (STAT3) protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6645</sb:first-page>
                              <sb:last-page>6668</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Crowe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Goldstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>41</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1181</sb:first-page>
                              <sb:last-page>1191</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.B.</ce:given-name>
                                 <ce:surname>Aggarwal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sethi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Ahn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Sandur</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting signal transducer and activator of transcription 3 for prevention and therapy of cancer: modern target but ancient solution</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. N. Y. Acad. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1091</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>151</sb:first-page>
                              <sb:last-page>169</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Drewry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Shahani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Cell. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>87</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>825</sb:first-page>
                              <sb:last-page>833</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antagonism of the STAT3-STAT3 protein dimer with salicylic acid based small molecules</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ChemMedChem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1459</sb:first-page>
                              <sb:last-page>1470</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Croucher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Haftchenary</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7190</sb:first-page>
                              <sb:last-page>7200</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The STATs of cancer-new molecular targets come of age</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>97</sb:first-page>
                              <sb:last-page>105</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Bowman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STATs in oncogenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2474</sb:first-page>
                              <sb:last-page>2488</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bromberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of STATs in transcriptional control and their impact on cellular function</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2468</sb:first-page>
                              <sb:last-page>2473</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Benekli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Baumann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wetzler</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting signal transducer and activator of transcription signaling pathway in leukemias</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4422</sb:first-page>
                              <sb:last-page>4432</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Avalle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pensa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Regis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Novelli</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT1 and STAT3 in tumorigenesis: a matter of balance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>JAK-STAT</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>65</sb:first-page>
                              <sb:last-page>72</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kraskouskaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Duodu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.C.</ce:given-name>
                                 <ce:surname>Arpin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Progress towards the development of SH2 domain inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Soc. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>42</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3337</sb:first-page>
                              <sb:last-page>3370</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Chou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hanafusa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Schaffhausen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cantley</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>SH2 domains recognize specific phosphopeptide sequences</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>72</sb:volume-nr>
                              </sb:series>
                              <sb:date>1993</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>767</sb:first-page>
                              <sb:last-page>778</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Becker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Groner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>Müller</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Three-dimensional structure of the STAT3 beta homodimer bound to DNA</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>394</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>145</sb:first-page>
                              <sb:last-page>151</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Mol. Recogn.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>254</sb:first-page>
                              <sb:last-page>265</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Herrmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Buettner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Revisiting STAT3 signalling in cancer: new and unexpected biological functions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>736</sb:first-page>
                              <sb:last-page>746</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Furtek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Backos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Matheson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Reigan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Strategies and approaches of targeting STAT3 for cancer treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>308</sb:first-page>
                              <sb:last-page>318</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.R.</ce:given-name>
                                 <ce:surname>Stark</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A low-molecular-weight compound discovered through virtual database screening inhibits STAT3 function in breast cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4700</sb:first-page>
                              <sb:last-page>4705</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4402</sb:first-page>
                              <sb:last-page>4412</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xia</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of an orally selective inhibitor of signal transducer and activator of transcription 3 using advanced multiple ligand simultaneous docking</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2718</sb:first-page>
                              <sb:last-page>2731</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Hutzen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ball</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zuo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Deangelis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neoplasia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>39</sb:first-page>
                              <sb:last-page>50</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Siddiquee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Guida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Blaskovich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Greedy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selective chemical probe inhibitor of STAT3, identified through structure-based virtual screening, induces antitumor activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>104</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7391</sb:first-page>
                              <sb:last-page>7396</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel small-molecule disrupts STAT3 SH2 domain-phosphotyrosine interactions and STAT3-dependent tumor processes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>79</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1398</sb:first-page>
                              <sb:last-page>1409</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.T.</ce:given-name>
                                 <ce:surname>Namanja</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Orally bioavailable small-molecule inhibitor of transcription factor STAT3 regresses human breast and lung cancer xenografts</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>109</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9623</sb:first-page>
                              <sb:last-page>9628</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel small molecule, XZH-5, inhibits constitutive and interleukin-6-induced STAT3 phosphorylation in human rhabdomyosarcoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1381</sb:first-page>
                              <sb:last-page>1387</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Canc. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>261</sb:first-page>
                              <sb:last-page>269</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.A.Z.</ce:given-name>
                                 <ce:surname>Siddiquee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Glenn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.P.</ce:given-name>
                                 <ce:surname>Katt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An oxazole-based small-molecule STAT3 inhibitor modulates STAT3 stability and processing and induces antitumor cell effects</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>787</sb:first-page>
                              <sb:last-page>798</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>125</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>538</sb:first-page>
                              <sb:last-page>550</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>124</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1006</sb:first-page>
                              <sb:last-page>1018</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>46352</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Jou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5592</sb:first-page>
                              <sb:last-page>5596</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kaptein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Paillard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Saunders</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dominant negative STAT3 mutant inhibits interleukin-6–induced Jak-STAT signal transduction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>271</sb:volume-nr>
                              </sb:series>
                              <sb:date>1996</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5961</sb:first-page>
                              <sb:last-page>5964</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Boatright</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Salvesen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mechanisms of caspase activation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>725</sb:first-page>
                              <sb:last-page>731</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.U.</ce:given-name>
                                 <ce:surname>Simon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hajyehia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Levischaffer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Role of reactive oxygen species (ROS) in apoptosis induction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Apoptosis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>415</sb:first-page>
                              <sb:last-page>418</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>